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Sixty-three hydantoin derivatives were evaluated for their modulating effects on efflux 
pump (EP) activity of Salmonella NCTC 13349 utilizing a semi-automatic fluorometric 
method. None of the compounds presented antibacterial activities at concentrations as 
high as 240 mg/L. Among all compounds, SZ-7 showed possible efflux modulating 
activity in the presence of glucose, indicative of a potential EP inhibitor. To verify its 
potential effects, ciprofloxacin-resistant Salmonella strains, induced to high level 
resistance with over-expressing EPs, were exposed to SZ-7. This derivative affected the 
susceptibility of the ciprofloxacin-resistant strains. 
Since the 63 compounds studied had very low inhibitory/accumulative effects, even 
though their known for being efficient in modulating ion-driven eukaryotic EPs, we 
questioned whether ions had a leading role in regulating bacterial EPs, influencing the 
effectiveness of new compounds. For this study we used Escherichia coli AG100 as a 
model, due to the extensive knowledge on its EPs structure and activity. 
Owing the importance of calcium ions (Ca
2+
) for membrane transport channels and 
activity of ATPases, the role of Ca
2+
 was investigated. From previous results we 
concluded that at pH 5 efflux is independent of metabolic energy; however, at pH 8 it is 
entirely dependent of metabolic energy and the Ca
2+
 ions are essential to maintain the 
activity of bacterial ATPases.  
Accumulation and efflux of ethidium bromide (EtBr) by E. coli AG100 was determined 
in the presence and absence of Ca
2+
, chlorpromazine (inhibitor of Ca
2+
-binding to 
proteins), and ethylenediaminetetraacetic acid (Ca
2+ 
chelator). Accumulation of EtBr 
increased at pH 8; however Ca
2+
 reversed these effects providing information as to the 
importance of this ion in the regulation of bacterial EP systems.  
Overall this work puts in evidence that many biochemical and bioenergetic aspects 
related to the strains physiology need to be taken into consideration in bacterial drug 






Sessenta e três derivados de hidantoína foram utilizados para avaliar possíveis efeitos de 
modulação na actividade das bombas de efluxo (BE) na Salmonella NCTC 13349 
utilizando um método fluorimétrico semi-automático. Nenhum dos compostos 
apresentaram actividade anti-bacteriana até concentrações de 240 mg/L. Entre todos os 
compostos, SZ-7 demonstrou possuir propriedades de modulação de effluxo na presença 
de glucose. Para testar esta actividade, estirpes de Salmonella resistentes à 
ciprofloxacina, induzidas a elevados níveis de resistência com sobre-expressão de BE, 
foram expostas ao SZ-7. Este derivado afectou a susceptibilidade das estirpes à 
ciprofloxacina.  
Uma vez que os 63 compostos estudados apresentaram pouco efeito 
inibitório/cumulativo, apesar de serem conhecidos pelos seus efeitos moduladores de 
BE-dependentes de iões em eucariotas, foi questionado o papel dos iões na regulação de 
BE bacterianas, que poderão influenciar a eficácia de novos compostos. Para este 
estudo, utilizamos a Escherichia coli AG100 como modelo, devido ao extenso 
conhecimento no que respeita a estrutura e actividade das BE.  
Devido à importância de iões de cálcio (Ca
2+
) nos canais de transporte membranar e na 
actividade de ATPases, a sua actividade na modulação do efluxo foi investigada. De 
resultados anteriormente obtidos concluiu-se que a pH 5 o efluxo é independente de 
energia metabólica; contudo, a pH 8 é absolutamente dependente, sendo que o Ca
2+
 é 
indispensável para manter a actividade das ATPases bacterianas.  
A acumulação/effluxo de EtBr pela E. coli AG100 foi determinada na 
presença/ausência de Ca
2+
, clorpromazina (inibidor de ligação de Ca
2+ 
a proteínas), e 
ácido etilenodiamino tetra-acético (quelante de Ca
2+
). Acumulação/effluxo aumentou a 
pH 8, contudo o Ca
2+
 reverte estes efeitos evidenciando a sua importância no 
funcionamento das BE bacterianas. 
Em resumo este trabalho colocou em evidência que muitos aspectos bioquímicos e 
bioenergéticos devem ser tomados em consideração no estudo da resistência bacteriana 
mediada por BE.  
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1. Enterobacteriaceae  
Enterobacteriaceae are a large and diverse family of Gram-negative bacteria, members 
of which are both free-living (distributed on plants, in soil and water) and part of the 
indigenous flora of humans and animals (15, 36, 38). They colonize the intestinal tracts 
of humans (58) but are relatively uncommon as normal flora of other body sites (15). 
They are among the largest bacteria, measuring 2 to 4 µm in length, with forms that 
range from large coccobacilli to elongated, filamentous rods (36, 58). They grow 
rapidly under aerobic or anaerobic conditions and are metabolically active, fermenting 
(rather than oxidizing) D-glucose and other sugars (15, 36), often with gas production 
(15). Most genera and species in this family include the following characteristics: do not 
form spores, are motile by peritrichous flagella or non-motile, are catalase positive and 
oxidase negative, reduce nitrates to nitrites (15, 36, 58), and have a 39 to 59% guanine-
plus-cytosine content of DNA (15).  
 
1.2. Virulence Factors  
The cell envelope of Gram-negative bacteria consists of an outer cell wall, a periplasmic 
space and the plasma membrane (54). They are protected by a thick double-membrane 
(26), which is highly hydrophobic due to the presence of a lipopolysaccharides (LPS), 
providing these organisms with a substantial permeability barrier (41, 88, 99). They 
constitute efficient obstacles towards hydrophilic molecules (10), most of which can 
gain access to targets beyond the outer cell wall via conduits that begin at the surface of 
the cell and end at the plasma membrane (54). On the other hand, they are easily 
crossed by amphiphilic compounds, since these are able to diffuse through both the 
hydrophilic and the hydrophobic domains of the bilayer. Therefore, it is not surprising 
that mechanisms were devised to protect cells from the disordered invasion by 
amphiphilic molecules, many of which are endowed with biological activities that lead 
to harmful effects (10). 
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Another important factor relates to the ability of these organisms to spread in the 
bloodstream producing an endotoxic shock, a potentially lethal manifestation of 
infection (36, 38). Endotoxins are pharmacologically active LPS contained within the 
cell walls of Gram-negative species (19, 36). These polysaccharides are structured into 
three regions: (1) an external variable portion of carbohydrate exposed to the 
environment and the defense system of a potential host that determines the antigenic 
specificity called the O antigen (e.g., multiple serotypes of Salmonella) (19, 36, 38), (2) 
a polysaccharide center or core which is structurally similar among species and (3) a 
highly conserved lipid portion called lipid A (27, 38). Motile strains have protein 
peritrichous flagella, which extend well beyond the cell wall and are called the H 
antigen (36). 
In addition to the LPS endotoxin common to all Gram-negative bacteria, some 
Enterobacteriaceae also produce protein exotoxins, which act on host cells by 
damaging membranes, inhibiting protein synthesis, or altering metabolic pathways, 
leading to cellular death or physiologic alteration (36). 
 
1.3. Epidemiology 
Most Enterobacteriaceae are primarily colonizers of the lower gastrointestinal tract of 
humans and animals (36), exposing it to harmful exogenous substances and functioning 
as a host defense/detoxification barrier (103). They can also be found in the female 
genital tract and as transient colonizers of the skin. Enterobacteriaceae are scant in the 
respiratory tract of healthy individuals; however, their numbers increase in hospitalized 
patients with chronic debilitating diseases (36).  
E. coli is the most common species of Enterobacteriaceae found among the indigenous 
flora, followed by Klebsiella, Proteus, and Enterobacter species. Salmonella and 
Shigella species are not considered members of the normal flora, although carrier states 
can exist (36). 
Statistically, several species of Enterobacteriaceae are very important causes of 
nosocomial infections, and account for nearly 50% of septicemia cases, more than 70% 
of urinary tract infections, and a significant percentage of intestinal infections (15). 
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They are the most frequently isolated bacteria from biological samples (38), often 
associated with abscesses, pneumonia, meningitis, septicemia, and infections of 
wounds, urinary tract, and the intestine (15).  
Therefore it comes as no surprise that the Infectious Diseases Society of America has 
recognized Gram-negative pathogens as some of the most problematic bacterial 
challenges (16, 18, 40). Not only is the increase emergence of resistance in Gram-
negative bacteria faster than in Gram-positive bacteria (21, 40), but also there are fewer 
new antibiotics active against Gram-negative bacteria and drug development programs 
seem insufficient to provide therapeutic cover in 10–20 years (40). This ineffectiveness 
is largely due to the excessive use of antibiotics in human therapy, as well as for farm 
animals, leading to a selection of pathogenic bacteria resistant to multiple drugs (68).  
 
1.4. Salmonella enterica and Escherichia coli 
An important property common to both species relates to the route of transmission 
(fecal-oral), which gives them the ability to survive in acidic environments (5, 43). With 
their passage into the small intestine, organisms will encounter a less acidic 
environment (pH 4 to 6) near neutral (5, 43), but one that includes the presence of 
fermentation end products (weak acids) produced by the normal intestinal flora. 
Although the pH of the intestinal contents is less acidic than that of the stomach, the 
presence of weak acids will increase acid stress to potentially lethal levels for enteric 
bacteria, such as E. coli and Salmonella spp. Nevertheless, these pathogens will survive 
gastrointestinal acidity and ultimately cause disease (43). 
1.4.1. Escherichia coli 
While recognized as a commensal organism, E. coli is by far the most common cause of 
urinary tract infections (36, 84). This organism shows marked tropism for different 
human epithelial cell types due to the presence of pili, which plays a key role in 
virulence (36) due to their capacity to adhere to host cells and to form biofilms (6). The 
P pili and type 1 pili are surface organelles attached to the outer membrane and 
frequently found on these uropathogenic isolates. Bacteria expressing P pili are most 
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commonly linked with infections in the upper urinary tract and kidney region causing 
pyelonephritis, while bacteria expressing type 1 pili are usually found in the lower 
urinary tract and bladder causing cystitis (6). 
Enteropathogenic and enterotoxigenic E. coli are a common cause of diarrhea (36, 84) 
in developing countries and for travelers. If antimicrobial therapy is indicated, the same 
agents are often used as for the treatment of urinary tract infections, i.e., 
fluoroquinolone, trimoxazole or nitrofurantoin (84). In children and the 
immunocompromised, E. coli can cause more serious infections, associated with higher 
morbidity and mortality. For these patient groups, antimicrobial treatment with a broad-
spectrum cephalosporin or a fluoroquinolone is required (84). 
Regarding resistance in E. coli, wild-type strains are resistant to most lipophilic 
antibiotics, which includes penicillin G, oxacillin, cloxacillin, nafcillin, macrolides, 
novobiocin, linezolid, and fusidic acid (68, 69).  
1.4.2. Salmonella enterica 
Based on iso-enzymes, rRNA sequences, and DNA hybridization, microbial 
taxonomists consider almost all of the Salmonella that infect mammals and birds to 
belong to one species – S. enterica. There are six subspecies of S. enterica including 
enterica, salamae, arizonae, diarizonae, houtenae, and indica (27). Within these six 
subspecies are over 2,000 serotypes of Salmonella (27, 90), as defined by the 
carbohydrate structures found in LPS and by flagella antigens. Nearly all the serotypes 
that cause disease in humans and domestic animals belong to subspecies enterica. 
Despite the fact that they are genetically closely related, there is enormous variation in 
the virulence and epidemiology of different serotypes of S. enterica (27). 
Until the 1980s S. enterica serovar Typhimurium (S. Typhimurium) was the most 
common serovar isolated from humans worldwide. However, in the late 1980s S. 
enterica serovar Enteritidis emerged as the most common cause of human salmonellosis 
and soon became the most prevalent serovar in many countries worldwide (12, 71). 
Salmonella is widespread in nature and can colonize or infect a wide variety of 
mammals, birds and reptiles (114), resulting in many different syndromes ranging from 
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colonization and chronic carriage to acute fatal disease (27). Salmonellosis designates 
the common food-borne infection caused by Salmonella spp in industrialized countries 
(61) that owes its large outbreaks to the ingestion of contaminated food of animal origin 
including eggs, meat, unpasteurized dairy products, seafood, fruits and vegetables (12, 
35, 114). 
Infection with Salmonella enterica serovar Typhi, which appears to be limited to human 
hosts, causes a spectrum of illness that includes diarrhea, a self-limited febrile illness, 
and most significantly, typhoid fever (29). 
Nontyphoid Salmonella are also responsible for enteric fever, gastroenteritis and 
bacteremia in humans and a broad array of illnesses in animals, including enteritis and 
septicemia in livestock (17, 27). However, non-typhoid Salmonella strains can also 
cause a variety of life-threatening extra-intestinal infections (27), since the spv 
(Salmonella plasmid virulence) genes appear to promote the macrophage phase of the 
disease process, avoiding destruction by neutrophils and facilitating proliferation at 
these sites of infection (17). A number of host factors can predispose to extra-intestinal 
Salmonella infections, including AIDS, hemolytic anemias, and genetic defects that 
affect IL-12, IFN-γ, and the phagocyte NADPH oxidase, but even in the susceptible 
host, certain serotypes of Salmonella are more likely to cause systemic infections (27).  
As for the recommended antimicrobial agents for severe Salmonella infections, 
ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol were used for many 
years. Rising rates of resistance has significantly reduced the efficacy of these agents 
(114), making fluoroquinolones (e.g., ciprofloxacin) the drug of choice for clinicians in 
early empirical treatment of severe gastroenteritis in adults (30, 35, 86).  
However, quinolone-resistant Salmonella strains have already been reported (61, 114), 
and the emergence of resistance or reduced susceptibility is particularly challenging, 
since this resistance is caused by mutations in the target enzymes, DNA gyrase and 
topoisomerase IV (30, 35, 44). Other mechanisms such as increased activity of efflux 
pumps (EPs), decreased permeability due to loss of porins and a variety of plasmid-
mediated quinolone resistance (PMQR) mechanisms also contribute to resistance and/or 
decreased susceptibility (35). 
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2. Mechanisms of Action and Resistance to Antibiotics 
Antibiotics have been highly effective in the treatment of bacterial infections; however, 
excessive use for many years has selected drug-resistant strains, creating a worldwide 
health issue (65, 71), in both medical and agricultural practices (49, 89). In this highly 
selective environment bacterium harboring resistance determinants obtain an advantage 
and will survive (109) the bacteriostatic or bactericidal effects of antibiotics and toxic 
effects of other drugs (71, 88).  
Among the major factors determining the frequency of resistance in a bacterial 
population are (i) the volume of antibiotic use, (ii) the costs of resistance to bacterial 
fitness, and (iii) the ability of bacteria to genetically compensate for such costs (14). 
As for the resistance mechanisms, these can be narrowed down to three main 
mechanisms. The first one involves the production of enzymes that inactivate antibiotics 
(42, 71, 89, 108) by hydrolysis or lead to the formation of inactive derivatives (71). 
A second mechanism consists in antimicrobial target alteration (42, 71, 89, 108) due to 
a mutation or enzymatic modification in such a way that the affinity of the antibiotic for 
the target is reduced (71). Resistance to macrolides, vancomycin, β-lactams, 
fluoroquinolones and aminoglycosides has been achieved by target-site alteration, while 
antibiotic inactivation mechanisms have accounted for resistance towards β-lactams, 
aminoglycosides and chloramphenicol (99). Nevertheless, these mechanisms provide 
resistance, but only to a single class of compound (99). 
The third mechanism of resistance prevents access of the unaltered antimicrobial from 
reaching its intended target (71, 108, 109) by either a decrease of permeability due to 
the outer membrane (108) or to the expression of porins (71, 108, 109), or by 
constitutive/inducible expression of active efflux systems that recognize the 
antimicrobial and extrude it (11, 89, 108). Porins consist of three outer membrane 
proteins (OMP) each one of which forms a barrel type structure within the internal 
cavity, allowing a large variety of hydrophilic compounds to pass through and reach the 
periplasm. The cell can respond to the presence of noxious agents by down-regulating 
their number (55). As a second line of defense to agents that manage to reach the 
periplasm or the cytoplasm, EPs which recognize the noxious agent can rapidly evade 
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the effects (31, 55) by extruding them to the medium in which the bacterium resides 
(55).  
Multidrug resistance typically results from the accumulation of multiple mutations 
and/or resistance genes (e.g., on integrons), but specific growth states (e.g., biofilms) 
and single mutations (e.g., impacting on outer-membrane permeability or the expression 
of broadly specific multidrug efflux systems) can also promote multi-resistance (89). 
However, it is the balance between the LPS layer of the outer membrane, general porins 
and the activity of the main efflux pump (EP) of the organism that generate the intrinsic 
resistance (2, 54, 109).  
 
2.1. Efflux Pumps 
Multidrug resistant (MDR) EPs are cytoplasmic transmembrane proteins (26, 39, 71, 
109) found both in Gram-positive and Gram-negative bacteria (39) capable of 
recognizing and expelling compounds (26, 39, 71, 109), by utilizing cellular energy (71, 
109).  
Although a variety of mechanisms account for distinct forms of resistance (44, 51, 65, 
66), the mechanism now broadly recognized as playing a major role in drug resistance is 
the over-expression of efflux transporters (47, 51, 65, 97) that (i) extrude a specific 
substrate or (ii) may transport a range of structurally dissimilar compounds before they 
reach their target (51, 79, 81, 84, 109). 
Antibiotic-specific EPs are usually encoded on transmissible plasmids and transposons 
(44), while genes encoding MDR pumps are normal constituents of bacterial 
chromosomes (44, 99). Thus, bacteria have the potential to develop multidrug resistance 
without acquirement of multiple specific resistance determinants. Genes encoding some 
MDR pumps are expressed constitutively in wild-type cells (44) and can be considered 
a ―general‖ resistance mechanism that cooperates with the target mutations, reduced 
membrane permeability or drug modifications (78). Thus, cells have basal levels of 
efflux activity, contributing to the decline in antibiotic susceptibility, even though the 
bacteria might remain susceptible to therapy. However, they would be even more 
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susceptible if EPs were rendered non-functional, allowing lower doses of antibiotics to 
be used in therapy (44). 
These membrane-spanning proteins involved in the outward transport of a surprisingly 
large variety of drugs have been recognized and characterized over the last years in 
almost all cell types, from prokaryotes and archaebacteria through fungi and higher 
eukaryotes. They can be classified on the basis of three main criteria, namely the energy 
source, the phylogenic relationship, and the substrate specificity (10). 
2.1.1. Classification of Multidrug Efflux Pumps 
Based on bioenergetic criteria, many of these integral membrane proteins can be 
broadly categorized into two main groups (45, 112), primary and secondary transporters 
(112). Primary transporters known as ATP-dependent transporters (45) are energized by 
the hydrolysis of ATP (25, 78, 112). Secondary transporters, on the other hand, harness 
energy stored in an electrochemical gradient generated by protons that are transported 
and distributed to the surface of the cell (2, 25, 42, 112), also known as proton motive 
force (PMF) (45). Membrane proteins coupled to electrochemical gradients provide 
pathways across the membrane for ion translocation, which occurs via a series of 
reversible binding events to specific sites (25). 
Based on genetic criteria, EP systems of bacteria are classified into five groups (2, 87) 
(shown in Figure 1) and, as previously described, sub-classified as to the immediate 
source of protons responsible for energizing the pump (2). 
EPs energized by protons under the control of the PMF are classified into four families: 
the major facilitator superfamily (MFS) (2, 42); the multi-antibiotic toxin extrusion 
(MATE) family (59, 71); the small multi-drug resistance (SMR) family (50, 62); and the 
resistance nodulation division (RND) family (75, 111). These transporters differ in size, 
ranging from about 1000 amino acids for the RND transporters, through 400–450 amino 
acids for the MFS and MATE transporters and down to 100 amino acids for the SMR 
transporters (59). 
The fifth family – ATP binding cassette (ABC) family – uses the hydrolysis of ATP by 




Figure 1 - Diagrammatic comparison of the five families of bacterial EPs (84). Abbreviations: MATE: multidrug 
and toxic compound extrusion, MFS: major facilitator superfamily, SMR: small multidrug resistance, RND: 
resistance-nodulation-division, ABC: ATB-binding cassettes. 
 
2.1.1.1. “ATP-binding cassette” (ABC) superfamily 
ABC transporters represent ubiquitous membrane systems (50) and constitute one of the 
largest super-families of proteins known (22) that utilize energy released from ATP 
hydrolysis (22, 70). 
Typically, ABC transporters involved in efflux of toxins, metabolites and drugs (50) 
appear to be made of four protein domains: two hydrophobic membrane-spanning 
domains presumed to constitute the translocation channel across the membrane; and two 
hydrophilic nucleotide-binding domains that interact at the cytoplasmic surface to 
supply energy for active transport by binding to ATP (22, 50). 
These transporters involved in drug resistance are mainly drug specific transporters 
since a number of them are found in antibiotic-producing organisms, mainly in 
Streptomyces spp., thus ensuring self-resistance to the drugs they produce (50). Specific 
transporters are also found in Staphylococcus and Enterococcus, conferring resistance to 
macrolides and bacitracin (50). In the Gram-negative bacterium Escherichia coli, there 
are approximately 80 ABC transporters (22). 
10 
 
2.1.1.2. “Major Facilitator” superfamily (MFS) 
This family is known to represent the largest group of secondary active transporters 
with well characterized multidrug pumps, including Bmr and Blt of Bacillus subtilis, 
MdfA of E. coli, LmrP of Lactobacillus lactis, NorA and QacA of S. aureus.  
The MFS consists of membrane transport proteins that are thought to function as 
monomers (42). They are found from bacteria to higher eukaryotes and are involved in 
the symport, antiport, or uniport of various substrates, such as sugars, Krebs cycle 
intermediates, phosphate esters, oligosaccharides, and antibiotics (50, 92). 
These proteins form two separate clusters, with either 12- or 14-transmembrane 
segments (TMS) (50, 62, 70, 92). MFS pumps with 14-TMS, represented by QacA and 
QacB, actively extrude monocationic biocides (10, 68) and dyes, such as benzalkonium 
chloride, cetyltrimethylammonium bromide, and ethidium bromide (68). MFS pumps 
with 12-TMS, although they have little relevance in the clinic, LmrP of Lactococcus 
lactis pumps out cationic dyes, daunomycin, tetracyclines, and macrolides, and MdfA of 
E. coli can confer increased resistance to cationic dyes, chloramphenicol, and 
fluoroquinolones when over-expressed from plasmids in a mutant strain lacking the 
constitutive RND pump AcrB (68).  
2.1.1.3. “Multidrug and Toxic Compound Extrusion” (MATE) family 
This family is represented by NorM protein of Vibro parahaemolyticus (34, 62), a 
protein with 12-TMS (70), that actively extrudes various compounds in exchange for 
the influx of Na
+ 
(42, 68), since they act mainly as Na
+
/drug antiporters (34, 50, 70). 
NorM and its E. coli homolog YdhE mediate resistance to dyes, hydrophilic 
fluoroquinolones, and aminoglycosides (92). 
Although there are only about 20 MATE transporters characterized to date, the bacterial 
genome sequences contain many more examples, and intriguingly, the MATE proteins 




2.1.1.4. “Small Multidrug Resistance” (SMR) family 
Multidrug transporters of the SMR family, the smallest secondary drug efflux proteins 
known, are typically about 107 amino acid residues in length (92) and contain only four 
TMS (50, 62, 68, 70). This family contains over 250 annotated members, and is now 
grouped into three subclasses: the small multidrug pumps, the paired SMR proteins, and 
suppressors of groEL mutant proteins (42). 
Due to the small size, it has been proposed that these pumps may function as homo-
oligomeric complexes (92), capable of extruding cationic compounds (10, 50, 68) such 
as quaternary ammonium biocides or ethidium (68). There is only one charged residue 
in the TMS, Glu14, which has an unusually high pKa of about 8.5. When the transporter 
encounters the substrate, this residue becomes deprotonated and instead binds the 
substrate. Thus, the inward flux of proton(s) and the outward flux of the substrate 
appear to be coupled by the sharing of a common binding site (68). 
2.1.1.5. “Resistance Nodulation Division” (RND) superfamily   
Drug exporters belonging to RND family, in particular AcrB and its homologues (65) 
are ubiquitous efflux systems among Gram-negative bacteria (13, 50) that function 
synergistically with the outer membrane to inhibit the accumulation of toxic molecules 
in the cell (13). 
These efflux systems are capable of recognizing and extruding a wide variety of 
unrelated compounds, such as antibiotics (42, 51, 65, 108), anti-cancer 
chemotherapeutics, toxic compounds (e.g.: anionic, cationic, zwitterionic and neutral 
compounds) (65), biocides, dyes (86) and other noxious agents like bile salts, resulting 
in a MDR phenotype when over-expressed (47, 51, 68, 108).  
This ―intrinsic resistance‖ to lipophilic antibiotics was often thought to be caused by the 
exclusion of drugs by the outer membrane barrier. However, the inactivation of the 
major RND pump AcrB of E. coli makes the bacteria almost completely susceptible to 
these agents even in the presence of the intact outer membrane barrier (69). Thus, the 
characteristic intrinsic resistance of Gram-negative bacteria to these antibiotics owes as 
much to the RND pumps as to the outer membrane barrier (68).  
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As shown in Figure 2, these transport systems form tripartite protein complexes (28, 42, 
52, 84) rather than a single transport protein (59). The RND pump in E. coli and other 
Gram-negative bacteria are composed of three components: AcrB – an inner-membrane 
protein (IMP) transporter (52, 59, 68, 79, 84) that captures substrates within either the 
phospholipid bilayer of the inner membrane or the cytoplasm (84, 106), TolC – an outer 
membrane protein (OMP) channel that traverses the cell envelope providing a conduit 
to the exterior, and AcrA –periplasmic membrane fusion protein (MFP) that anchors 
TolC to the plasma membrane (52, 59, 68, 79, 84), allowing the cooperation between 
AcrB and TolC (65, 84). In E. coli, TolC has the ability to interact with different classes 
of inner-membrane proton antiporters, which may belong either to the RND family or 
the MFS (26). 
 
Figure 2 - Schematic representation of the tripartite efflux system AcrAB-TolC (a) The model of the AcrB-
AcrA-TolC tripartite complex that exports drugs directly into the medium. (b) AcrB trimer. Each protomer is shown 
in a different color. The large central cavity is connected to the periplasm through vestibules between protomers. The 
proximal portion of the structure was cut away to reveal the presence of vestibule. (c) The periplasmic domain of the 
asymmetric AcrB trimer viewed from the top. The conformation of each protomer is characteristic, with open or 
closed external clefts. A drug molecule is seen bound to the binding protomer (68). 
 
The AcrAB-TolC system is highly homologous to the MexAB-OprM RND system in P. 
aeruginosa (70, 84). AcrA is a 397-amino acid protein that interacts with AcrB, a much 
larger protein with 1,048 amino acids (84). TolC, a 506-amino acid (84) homotrimeric 
exit duct, that looks like a uniform tube with a 40Å thick β-barrel penetrating the outer 
membrane (66, 78) and a 100Å long periplasmically protruding tube surrounding six 
coiled coils (66), which interacts with the periplasmic adaptor and/or the inner-
membrane transporter leading to the conformational changes (78, 84). AcrA is 
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presumed to be a highly elongated molecule that can span the periplasmic space, 
suggesting that AcrB might directly dock with TolC and that AcrA might reinforce the 
docking at the side of the complex (66). These transporter proteins are composed of 12-
TMS with two large periplasmic domains that possibly provide substrate specificity 
(Figure 3) (50). 
 
Figure 3 – Structural model for multidrug transporters of the RND family. The residues constituting the 
conserved sequence motifs are shaded (92). 
 
This construction allows the direct and efficient export of drugs into the external 
medium, rather than into the periplasmic space (10, 50, 68, 70). This provides a huge 
advantage for bacterial cells since once exported into the external space drug molecules 
must traverse the outer membrane barrier to reenter bacterial cells. Thus, these pumps 
work synergistically with the outer membrane barrier (68, 69) that acts as an additional 
protective step limiting the passive penetration of hydrophilic and hydrophobic 
molecules (47). 
Also, substrates might access the AcrB central cavity either from the cytoplasm through 
the trans-membrane region or from the periplasm through the AcrB lateral vestibules 
(66, 68, 78, 81). This was predicted because carbenicillin, which cannot cross the 
cytoplasmic membrane owing to the presence of two carboxylate groups, is still a good 
substrate for these pumps (68, 81). This allows the pumps not only to prevent the entry 
of drugs into the cytoplasm, but also to extrude agents, such as β-lactams, whose targets 
are on the outside surface of the cytoplasmic membrane (66, 68, 81). Importantly, the 
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periplasmic capture mode allows the RND tripartite pumps to collaborate 
synergistically with simple EPs that extrude substrate drugs only into the periplasm 
(68). 
As previously described, RND pumps are proton antiporters (52, 65, 84), that utilize the 
trans-membrane proton gradient (26) across the membrane to power efflux, exchanging 
one H
+
 ion for one drug molecule (52, 84). The membrane surface is separated from the 
bulk aqueous phase by an electrostatic barrier of ions (63). This gradient provides the 
protons present in the periplasmic space and, when they enter the transporter at its 
plasma membrane base, they energize the pump (2, 52) and the agent which is believed 
to be concentrated within the inner membrane is in turn extruded. The proton is then 
released to the medial side of the plasma membrane. The fusion proteins are believed to 
physically assist the extrusion of the agent (52).  
The PMF is maintained by the metabolic activity of the bacterium and is in part 
established by protons generated in the inner membrane following the hydrolysis of 
ATP (54) catalyzed by membrane bound ATPases and by oxidative metabolism (52).  
After the protons are exported to the periplasm by a variety of transport processes (2, 
52), most are then exported to the surface of the cell,
 
distributed on its surface and 
bound to reactive groups of the outer cell wall (LPS and -CO2
−
) (54), creating a proton 
gradient that is greatest at the surface of the cell and least in its periplasm (2, 52). The 
proton translocation is driven by membrane-associated proteins that couple electron 
flow from low–redox potential electron donors to higher-potential electron acceptors 
(95). This distribution establishes a relative negative charged periplasmic space and 
positive charged surface of the cell, resulting in an electrochemical gradient (2, 52, 54), 
which can be maintained at extreme pH and temperature (2).  
The resulting trans-membrane difference in the electrochemical potential of hydrogen 
ions was at first seen to be the driving force behind the energy consuming enzymes and 
ATP-synthase and was defined as the proton motive force (PMF). However, because of 
the largesse of the bulk water phase the dissemination of protons from the surface of the 
cell would quickly eliminate the pH gradient across the cell envelope, and hence, the 
PMF and the energy it provides for driving EPs would be eliminated. Because the PMF 
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is maintained by the bacterium when challenged by changes in the pH of the 
environment, the chemiosmotic theory should possibly include the concept that the 
distribution of protons on the surface of the cell which due to the lipopolysaccharide 
components of the outer cell envelope, would be selectively concentrated (2, 52) and 
result in a pH of the medium immediately surrounding the surface of the cell that would 
be much lower than the pH of the bulk medium (52, 54). This surface distribution of 
protons therefore assists the bacterial cell in maintaining a PMF that would not be 
significantly affected by the pH of the medium (52). In conclusion, the PMF is therefore 
composed of a chemical proton gradient (ΔpH, inside alkaline) and an electrical 
potential (ΔΨ, inside negative) (92). 
 
2.1.2. Efflux systems in E. coli and Salmonella enterica 
These transporter proteins thought to play a crucial role in antibiotic resistant food-
borne pathogens are isolated both from humans and from animals capable of spreading 
from one ecosystem to another (84).  
Drug efflux systems in E. coli have been used as models for genetic and biochemical 
studies (42). The complete genome sequence of E. coli was determined by Blattner et al. 
in 1997 and its analysis revealed 37 putative drug transporter genes from the five 
families: 19 of the MFS, 3 of the SMR, 7 of the RND, 7 of the ABC, and 1 of the 
MATE (70). The transport systems of these genes were classified according to the 
putative membrane topology, protein family, bioenergetics, and substrate specificity 
(82).  
In E. coli, there are approximately seven different proton-dependent MDR pump 
systems that can export structurally unrelated antibiotics (101, 106): AcrAB-TolC, 
EmrAB, MdfA, TehA, EmrE, AcrEF, and EmrD (101). All of the above fall into three 
distinct families, encoded by the following genes: the major facilitator superfamily 
(MFS: emrD, mdfA, emrB), the resistance nodulation-cell division family (RND: acrB, 
acrF, acrD, yhiV), and the small multidrug resistance family (SMR: emrE, tehA) (101, 
106). Putative ATP-dependent drug EPs in E. coli have also been identified by Paulsen 
et al. (82), including YhiG, MdlB, YbjZ, and MsbA (101). 
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Legend: AC, acriflavine; AG, aminoglycosides; AH, aromatic hydrocarbons; BA, benzalkonium; BL, b-lactams; 
BS, bile salts; CH, cholate; CM, chloramphenicol; CV, crystal violet; DOC, deoxycholate; DOX, doxyrubicin; ER, 
erythromycin; EtBr, ethidium bromide; FA, fatty acids; FQ, fluoroquinolones; FU, fusaric acid; LN, linezolid; ML, 
macrolides; MX, methotrexate; NAL, nalidixic acid; NOR, norfloxacin; NV, novobiocin; PO, pine oil; RD, 
rhodamine; RF, rifampicin; SDS, sodium dodecyl sulphate; TC, tetracycline; TP, trimethoprim; TS, triclosan; TX, 
Triton X-100. 
 
Even in the presence of a variety of MDR pumps, with respect to E. coli, extrusion of 
noxious agents is performed primarily by the over-expression of the acrAB locus 
encoding the multidrug EP AcrB, controlled by the marRAB operon, although other EPs 
may assist in the extrusion process (52, 85).  
As mentioned earlier, the E. coli AcrB can pump out a very wide range of compounds, 
including lipophilic drugs, detergents (including bile salts), dyes and even solvents (as 
seen in Table 1) (68, 84, 97).  
 
Table I – Bacterial EPs involved in antibiotic resistance by E. coli and respective characteristics. Properties EPs 
are shown together with the periplasmic adaptor protein (MFP) and the outer membrane channel (OMF) they interact 






Genes MFP OMF 
AcrB AcrA TolC 
AC, AH, BA, BL, BS, CM, CV, EtBr, ER, 
FA, FQ, FU, LN, ML, MX, NV, organic 
solvents, penicillins, PO, SDS, TC, TP, TS, 
TX 
acrR, marA, 
robA, soxS, sdiA 
AcrD AcrA TolC AG, DOC, FU, NV, SDS, BL 
sdiA, baeR, cpxR, 
ompR 
AcrF AcrE TolC 









TolC NV, BL, BS, SDS baeSR 
YhiV YhiU 
TolC 








E. coli over-expressing AcrAB demonstrates increased resistance to substrates such as 
bile salts, when compared to an isogenic wild-type strain; and similarly, a strain with an 
acrAB deletion is more susceptible than the wild-type strain to the same compounds 
(101).  
The expression of homologs such as AcrD can become increased through regulatory 
responses or mutations (68) in the presence of aminoglycosides which they are capable 
of extruding (a function that could not be carried out by the AcrB pump) (68, 84). 
The AcrE and AcrF pumps also mentioned above are 80 and 88% similar to AcrA and 
AcrB, respectively (84). In particular, the AcrEF-TolC system can extrude similar 
substrates (e.g., lipophilic and amphiphilic agents (97)) albeit at lower efficiency levels. 
Moreover, these pumps can be over-expressed when AcrAB is deleted or inactivated 
(79). Therefore, acrAB or acrEF deletion mutants are increasingly susceptible to a wide 
variety of antibiotics and detergents and could be made significantly more resistant to 
these substances by the respective insertion of acrAB- or acrEF-carrying plasmids 
(106). However, although increased expression of AcrEF results in increased resistance 
to some AcrAB substrates, deletion of acrEF does not contribute to increased 
susceptibility to those substrates (101), demonstrating that the AcrAB-TolC pump is the 
dominant MDR pump among other pumps (65, 101). 
Even so, it should be again noted that the over-expression alone of the AcrAB-TolC 
system is unlikely to give rise to clinically significant levels of resistance (84). For 
example, fluoroquinolone resistance in E. coli can be caused by mutations in the target 
topoisomerases of the drugs, DNA gyrase (e.g., in gyrA) and topoisomerase IV (e.g., in 
parC), or they can affect regulatory genes such as marA or soxS. Overexpression of 
marA causes decreased expression of the OmpF porin as well as increased expression of 
the multidrug EP AcrAB, thereby conferring resistance (42, 73). A mutation in a 
topoisomerase gene which affects the capability of fluoroquinolones is unlikely to give 
rise to clinically significant levels of resistance; however, when combined with an over-
expressed AcrAB-TolC system, such isolates are resistant to the breakpoint 
concentration of ciprofloxacin (84).  
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Efflux may cooperate with other resistance mechanisms to confer not only high level 
but also broad-spectrum resistance. In E. coli, expression of class-C β-lactamase confers 
resistance to first- and second- generation cephalosporins, and expression of pump 
AcrB causes resistance to most penicillins. The global result is that the organism 
becomes susceptible only to third- or fourth- generation cephalosporins (11). 
 
On the other hand, Salmonellae also possess multiple drug efflux systems (42). At least 
nine drug EP genes exist in Salmonella enterica, eight of which are also found in E. coli 
(71).  
Due to efflux mechanisms, adaptive resistance to a variety of compounds like 
benzalkonium chloride and triclosan, and to agents used in treating infections in poultry 
like fluoroquinolones, β-lactams, macrolides (e.g., erythromycin), and tetracycline are 
substrates for MDR EPs identified in Salmonella spp (42, 84).  
Previous studies have discovered that Salmonella responds to acidic challenges through 
an adaptive system called the acid tolerance response in which adaptation to mild acid 
conditions enables the organism to survive periods of severe acid stress (83). Ingested 
Salmonella must survive the acidic environment of the duodenum, which receives bile 
salts that are toxic to the organism. When it reaches the colon, the pH is near neutral but 
due to the presence of bile salts the environment remains toxic (5).  
The means by which the organism escapes injury from bile salts is by the activity of its 
AcrAB–TolC EP, which extrudes the noxious compounds prior to their reaching their 
intended targets. It has been suggested that as long as the organism is located in the 
colon, the activity of the AcrAB–TolC EP also protects it from antibiotics, rendering 
therapy of salmonellosis a serious problem (5). 
Additional studies demonstrate that when either the acrD or acrF genes are deleted, the 
AcrB expression is increased; likewise, when acrB gene is deleted, expression of AcrD 
or AcrF increases. However, a double-knockout mutant lacking AcrB and AcrF is no 
more susceptible than a construct lacking AcrB alone. These data suggests that the 
major EP in S. enterica serovar Typhimurium, and probably all serovars of S. enterica, 
is again the AcrAB-TolC pump (5, 84).  
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The ability of Salmonella to cause infection in humans is also due in part to its ability to 
survive within the phagolysosome of the neutrophil (21). Survival within the 
phagolysosomal compartment results from activation of the two-component regulatory 
system PmrA/B (21, 83), an operon that involves at least nine genes resulting in the 
synthesis and insertion of lipid A into the nascent lipopolysaccharide layer of the cell 
envelope. This response renders the organism resistant to enzymatic digestion, to other 
antimicrobial proteins as well as many antibiotics (21).  
 
2.1.3. Efflux pump systems: Physiological Importance 
Despite compelling evidence implicating EPs in multidrug resistance, the ongoing 
debate concerning the ―natural‖ function of these proteins has not abated (71, 89). 
Clearly the RND-type multidrug pumps have not appeared in response to the 
widespread use of antibiotics and for drug resistance (42, 68), as most of these pumps 
are coded by chromosomal genes that are present in strains isolated long before the 
antibiotic era (68).  
As discussed previously, MDR EPs can recognize a wide range of structurally unrelated 
substrates including those compounds produced by higher organisms, such as bile salts 
(42, 71), fatty acids and hormones (42), and extrude them prior to its reaching sensitive 
and lethal targets within the bacterium (52, 68). They can also respond to a range of 
stimuli including stress signals, and influence the colonization (42), pathogenesis or 
virulence (42, 71), cell communications, biofilm formation and other fitness responses. 
These functions may well be the physiological functions of at least some of the drug 
pumps, and may ensure the persistence of drug efflux transporters in evolution. Thus, 
pumps are likely to affect the interaction of bacteria with its host (42).  
The observed inducibility of the E. coli AcrAB system by toxic fatty acids, and the 
demonstrated role of AcrAB in the export of and resistance to bile salts (86, 89) (present 
the highest affinity, among substrates, to the AcrB transporter (68)), have been cited as 




Also, exposure of Salmonella to low pH is well known to activate the PmrA/PmrB, a 
regulatory system which not only allows the organism to survive the low pH of the 
phagolysosome, but also increases its resistance to antibiotics. Exposure of E. coli to 
low pH activates a wide spectrum of genes, some of which code for cell envelope 
proteins. These studies suggest that low pH readily activates genes of a Gram-negative 
bacterium and render the organism resistant (52). 
Export of bacterial products is also a proposed function for these multidrug efflux 
systems, with a previous review implicating byproducts of metabolism as probable 
substrates for these efflux systems. The up-regulation of the E. coli AcrAB efflux 
system in strains with mutations in central biosynthetic pathways, possibly as a result of 
accumulation of pathway intermediates, certainly supports this idea (89). 
 
Understanding the physiological roles of the MDR pumps may continue to be rather 
difficult as the functions of these pumps are often involved in a complex, and 
overlapping network of reactions in the bacterial cell (42). There is clearly a lack of 
evidence for the induction of efflux gene expression by antibiotics (86, 89), despite the 
fact that most of the pumps are regulated, often by the product of a linked regulatory 
gene (87). If antibiotics are not the ‗signal‘ for pump expression, elucidating this signal 
is likely to be very useful in discerning the natural function of these efflux mechanisms 
(87). 
2.1.3.1. Importance of Calcium Regulation 
Over the years, a number of bacterial proteins have been identified to be involved in 







), primary and secondary transporters, and Ca
2+
-binding proteins (CaBPs), 
which may be involved in Ca
2+
 homeostasis (23, 110). The idea that Ca
2+
 acts as a 





]i) (23), in order to control many cellular 
processes in eukaryotic transport systems (37). 
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Much evidence supports the role of Ca
2+
 as a regulator in prokaryotes however, the 
extent and importance still remains unclear. It is known that bacteria keep tight control 
of their [Ca
2+
]i with values very similar to those found in eukaryotes (100–300 nM) (23, 
105).  
There is data that supports the involvement of calcium in a number of bacterial 
processes such as maintenance of cell structure, motility, transport, cell division, gene 
expression and cell differentiation processes such as sporulation, heterocyst formation 
and fruiting body development (23). It is vital for signaling and activating genetic 
systems as well as a broad range of metabolic and energy providing pathways within the 
cell (67, 72). Additionally, the growing number of proteins containing various Ca
2+
-
binding motifs supports the importance of Ca
2+
, which controls various protein 
functions by affecting protein stability, enzymatic activity or signal transduction (60). 
Recently, Jones et al showed that the periplasm can accumulate Ca
2+
 ions three- to 
sixfold when compared to the external medium by performing [Ca
2+
]i measurements in 
the E. coli periplasm (33). These findings suggest that both the outer membrane and the 
periplasm could be crucial for Ca
2+
 regulation by acting as Ca
2+
 barriers or buffering 
and sorting Ca
2+




 transporters in 
the inner membrane (23, 33). 
 
3. MDR Efflux Inhibitors  
The expanding problem of MDR EPs and their ability to decrease intracellular 
concentration of active antibiotics has required the development of new therapeutic 
treatments (13). In order to address this problem, it is necessary to search for and 
develop new molecules to circumvent efflux activity (47), either by modifying existing 
antibiotics or by discovering and developing therapeutic agents which inhibit the 
transport activity of EPs and could be used in combination with existing antibiotics 
(44).  
To specifically block the activity of drug EPs, there are different possibilities (i) avoid 
efflux activity and thus, enhance the activity of multiple substrates by reducing their 
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efflux; (ii) decrease the permeability efficacy of the membrane barrier (44, 47); (iii) 
block the efflux capacity of bacterial cell by altering the pump function (47, 78). 
Regarding the approach based on the inhibition of EPs, the antibiotic is co-administered 
with an inhibitor that neutralizes efflux based resistance, rendering the antibiotic useful, 
even in resistant organisms (50, 13). Such molecules, the efflux pump inhibitors (EPIs), 
are expected to: (i) decrease the intrinsic resistance of bacteria to antibiotics by 
increasing the intracellular concentration, (ii) reverse acquired resistance even in highly 
resistant strains with multiple target mutations, (iii) and reduce the frequency of 
emergence of resistant mutant strains (50, 47). The net result of blocking the efflux of 
an antimicrobial compound by the use of EPIs is to decrease the threshold concentration 
(i.e. the minimum inhibitory concentration (MIC)) of the antimicrobial compound (13). 
Several classes of compounds that block efflux by the RND efflux systems have been 
identified in screens of chemical libraries (50, 13) or in biodiversity-issued compounds, 
which could be further optimized by structure–activity relationships studies (50) and 
therefore potentiate antibiotics that are RND efflux substrates (13). 
 
Nevertheless, while very compelling scientifically and of clear potential clinical benefit, 
this approach brings with it many challenges. Besides the obvious issues common to all 
infectious disease drug development programs (appropriate potency, spectrum of 
activity, bioavailability, clearance, toxicity, etc.), several are specific to this strategy. In 
the discovery phase, the pharmacokinetics of the EPIs must be taken into account and 
viable pharmacokinetic profiles of the potentiator may be significantly restricted as a 
result. In development, clinical trials must be designed to demonstrate improvement of a 
combination product over existing therapies (44). 
The search for newer antimicrobials has also prompted studies demonstrating that many 
medicinal compounds belonging to various pharmacological groups, such as 
tranquilizers, antihypertensives, antipsychotics, non-steroidal anti-inflammatory agents 
(NSAIDs), mucolytic agents, calcium channel blockers, cardiovascular drugs, proton 
pump inhibitors and even antispasmodic agents have some influence on the physiology 
and on the viability of microorganisms, thus the name ‗non-antibiotics‘ (21, 64). The 
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use of these drugs in combination with antibiotics possess the advantage of being cost-
effective and time-saving, since a lot of data is already available, with respect to toxicity 
and pharmacokinetics (50). 
Some EPIs have been identified over the past decades, including phenylalanyl arginyl-
β-naphthylamide (PAβN) verapamil, phenothiazines (e.g., thioridazine (TZ) and 
chlorpromazine (CPZ)), and compounds isolated from plants (55). However, to date no 
EPI has been licensed for use in the treatment of bacterial infections in human or 
veterinary medicine, and it is clear that this gap must stimulate research that leads to the 
development of new EPI molecules (47). 
 
3.1. Calcium channel inhibitors 
3.1.1. Phenothiazines 
Phenothiazines, a group of antipsychotic drugs commonly used to treat certain mental 
disorders (37) due to the neuroleptic properties of methylene blue (4, 104), were found 
to interact strongly with calmodulin, a Ca
2+
 -binding protein that modulates a number of 
proteins regulating cellular functions (37). These calmodulin antagonists and other 




 since they inhibit the binding of 
Ca
2+
 to calmodulin or calmodulin-type proteins (4, 55). The inhibition of calcium access 
to Ca
2+
-dependent ATPase inhibits transport processes such as those performed by 
influx and EPs (55). Since phenothiazines specifically inhibit binding of calcium to 
calcium-dependent enzymes, they inhibit their activity and, hence, the transport 
processes (54, 55). 
The potential use of phenothiazines as antibacterial agents or as enhancers of antibiotic 
activity lies in their ability to kill phagocytosed bacteria, namely in Mycobacterium 
tuberculosis and Staphylococcus aureus. This occurs due to the ability of the 
macrophage to concentrate the phenothiazine to a level comparable to a minimal 
bactericidal concentration (4). Thus, Gram-positive cocci, Mycobacteria and some 
Gram-negative rods, such as Shigella spp., are more susceptible to the antibacterial 
properties of a number of phenothiazines, opposed to Gram-negative rods such as 
Escherichia coli and Salmonella spp. (4). 
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However, phenothiazines can interfere by other means. In Gram-negative bacterium 
such as E. coli, β-lactams specifically bind to penicillin-binding protein (PBP) 3, which 
is associated with the filamentation of the bacterium. Since phenothiazines also affect 
filamentation, they may either bind directly to a PBP or have some effect on other 
mechanisms that indirectly influence the PBP. 
It is worth noting that filamentation of Gram-negative bacteria can also be produced by 
non-β-lactam antibiotics (e.g., quinolones), as well as by physical conditions (e.g., 
release from hydrostatic pressure) and by growth conditions, therefore filamentation 
caused by sub-inhibitory concentrations of a phenothiazine may not involve a direct 
effect on the PBP itself (4).   
With respect to the adherence of Gram-negative bacteria, phenothiazine Promethazine 
has shown the ability to reduce the effect on epithelial cells. It prevents the recurrence 
of pylonephritis caused by E. coli and, since the concentration required to inhibit the 
growth of bacteria is well beyond that clinically relevant, the successful therapy of 
recurrent pylonephritis is possibly due to the effect it has on the adherence of E. coli to 
the epithelium of the urinary bladder (4). It seems plausible that phenothiazines inhibit 
adherence by inhibiting pili formation, which is also true with low concentrations of 
antibiotics, as well as by interfering with access of bacterial pili to receptors present on 
the surface of the epithelial cell (4). 
3.1.1.1. Chlorpromazine   
Chlorpromazine (CPZ) was introduced by Rhone-Poulenc in the early 1950s (4, 64, 76) 
as a neuroleptic drug employed for the management of psychosis (3). CPZ as well as 
other phenothiazines such as thioridazine (TZ), promazine, promethazine and 
desipramine present antimicrobial properties in vitro against a variety of bacteria (4, 76) 
due to its capacity to affect the ultra-structure of the cell wall (3). 
CPZ inhibits the binding of calcium to calcium binding proteins of eukaryotes and 
prokaryotes. As a consequence of its inhibitory properties, CPZ also inhibits bacterial 
kinases and phosphatases, calcium and potassium transport (2). 
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CPZ is concentrated in excess of 100-fold by tissues and organs rich in macrophages 
and in vitro concentrations that are within clinical reach are effective against 
phagocytosed organisms (76). Studies have also shown that CPZ has the ability to 
inhibit the in vitro growth of mycobacteria, inhibit the secretion of toxins, cause the 
elimination of plasmids from infected Gram-negative bacteria, cause the lysis of 
bacteria, increase the permeability of bacteria to agents, reverse resistance to antibiotics 
and inhibit bacterial enzymes (2).   
When E. coli is exposed to sub-MIC levels of CPZ, regardless of its resistance to CPZ, 
it will exhibit elongation and of significant importance, exhibit far greater sensitivity to 
antibiotics to which it is sensitive, lowering the MIC values (3). The effects of CPZ on 
E. coli were noted in the protein composition of the plasma membrane; alterations 
which may be related to the inhibitory effects of CPZ on the EP which in turn was 
postulated to result in greater retention of antibiotic within the cytoplasm, enhancing 
antibiotic activity with the co-presence of CPZ (3). 
However, because prolonged use of CPZ produced a number of serious side-effects (4), 
and whatever antimicrobial activity reported was essentially one produced only in vitro 
at concentrations beyond clinical reach (4, 76), CPZ and other phenothiazines were not 
seriously considered as potential sources of new antibiotics, even when they were 
shown to have desired antimicrobial effects in vivo (4).  
 
3.2. Novel Compounds  
Given the development failure of new antibiotics and the emergence and spread of 
MDR bacteria, there is a vital need to identify clear targets to block efflux mechanism, 
and select molecules with a high inhibitory efficacy and no toxic effects on mammal 
cells, a field that remains undefined and vague (115). 
While resistance to naturally-occurring antibiotics is prevalent in the soil environment, 
genes conferring resistance do not seem to take over and fixate in these natural 
populations; instead resistant and sensitive bacterial strains coexist. Possibly, while 
antibiotics select for resistant strains, other natural mechanisms may perhaps exist to 
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choose against resistance (80). This ability to select for or against resistance depends on 
the selective pressure the new compound applies and on the duration of its activity, 
determined by its chemical stability (80).  
In the natural environment, antibiotics are not static - a single drug can decay into a 
range of compounds, each accumulating and degrading with different kinetics and 
displaying different selective effects (80). Due to the short-life of antibiotics, they decay 
to an assortment of chemical species which may be more stable than the precursor drug, 
and may therefore have significant ecological impacts. Thus, competition between 
antibiotic resistant and sensitive strains may be influenced both by the short-term effect 
of an antibiotic and by the potential long term effects of its degradation products (80).  
3.2.1. Hydantoin compounds 
Many hydantoins derivatives find important applications as medicinal (anticonvulsant 
drugs in the treatment of epilepsy, anti-arrhythmic (7, 8, 9), antitumor, anticancer (7, 
91), anti-inflammatory (8, 9, 91), anti-muscarinic, anti-ulcers, anti-viral, anti-diabetic 
(8) and antiandrogens drugs (9)) and as agrochemicals (bactericides, fungicides (7) and 
as aldose reductase inhibitors (9)).  
As an anticonvulsant drug, it is very effective in controlling a variety of seizure 
disorders while impairing little neurologic function, if at all (20). This modulation of the 





 ions, whose conductance are important during the function of excitable nerve, 
heart, and muscle tissues. Early work suggested the hypothesis that the effects were due 
to a selective block of high-frequency neuronal activity by selective modulation of 
eukaryotic ion-driven EPs (20). As an antimicrobial, hydantoin compositions are 
generally added to industrial aqueous fluid media to reduce or inhibit the growth of 
microorganisms (48). 
Hydantoins and thiohydantoins are compounds that possess a reactive urea core. They 
are an important structural moiety found in several natural products and 
pharmacologically important compounds (9). In recent years, considerable efforts have 
been devoted to the development of novel and more efficient methods for synthesis of 
27 
 
(thio)hydantoin derivatives (7), due to their importance as substrates for enzymatic 
reactions (1). 
Synthetically, hydantoins are important precursors of amino acids, via either acid-, 
base- or enzyme-catalyzed hydrolysis. The Bucherer–Bergs reaction is the most 
commonly used method for the synthesis of hydantoins. This multi-component reaction 
starts from an aldehyde or a ketone whose ready availability makes the Bucherer–Bergs 
reaction an attractive method for the synthesis of hydantoins. However, the use of 
potassium cyanide (KCN) leads to safety problems, causing the reaction to be 
conducted within a sealed tube at a temperature of 80ºC. Other methods furnishing 
hydantoins include the treatment of amino amides with triphosgene, the reaction of 
amino acids with acetic anhydride and ammonium thiocyanate (to create the 
thiohydantoins), the combination of carbodiimides with unsaturated carboxylic acids, 
and the treatment of nitriles with organometallic reagents followed by addition of 
potassium cyanide and ammonium carbonate (9). 
Within certain species of bacteria, the hydantoin substrate compounds are first 
hydrolyzed by hydantoinase enzymes in a ring-opening step (1, 24, 102) to form either 
L- or D- N-carbamoyl-α-amino acids (i.e. hydantoic acids) (1, 24, 93, 102). Hydantoin-
cleaving enzymes can often be found in combination with highly stereoselective N-
carbamoyl-α-amino acid amido hydrolase (N-carbamoylases) enzymes, which catalyze 
the further hydrolysis of the hydantoic acids to the free D- or L-amino acids in an 
irreversible reaction (1, 102), as presented in Figure 4. 
Together, these microbial hydantoin-hydrolysing enzyme systems (32) accomplish the 
total conversion of D, L-5-monosubstituted hydantoin compounds to produce optically 
pure D- or L-amino acids (1, 32, 93, 102), important intermediates for the production of 
various drugs and pharmaceuticals (32, 102). For example, D-Hydantoinase, together 
with N-carbamoyl-D-amino acid hydrolase is used in the production of D-amino acids 





Figure 4 - Reaction scheme for the enzymatic cleavage of D, L-5-monosubstituted hydantoin derivatives to the 
corresponding D- or L-amino acids. AA: amino acid (1). 
 
The most common anomalies seen in patients exposed to hydantoins occur during 
pregnancy with deficiency in growth. Cleft lip and palate, developmental delay, mental 
retardation, and mid-face hypoplasia are also supportive of the diagnosis. Exposure of 
the embryos to the action of hydantoin decrease the embryo‘s survival rate and weight 
and induce neural development retardation and abnormal morphogenesis (20). 
Nevertheless these compounds are considered to be good candidates for new EPIs since 
their mechanism of action is similar to the one described for other know eukaryotic 
EPIs such as the phenothiazine group, with potential to be used to inhibit efflux activity 
of prokaryotic EPs (46, 98). 
 
4. Detection methods of accumulation and efflux in bacteria 
4.1. Semi-automatic fluorometric method to monitor ethidium bromide transport 
through bacterial membranes 
A semi-automated fluorometric method recently developed by the Group of 
Micobacteria of the Unit of Microbiology of the IHMT/UNL, uses the universal EP 
substrate EtBr for the real-time assessment of EP activity in bacteria (2, 31, 96, 108). To 
enable this, the method employs the Rotor-Gene 
TM
 3000 thermocycler (Corbett 
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Research) capable of evaluating the EP activity in vivo and on-line of a large number of 
samples, with the possibility to expose the same cell preparation to different 
physiological conditions in a single assay (2, 79) (e.g., temperature, pH, presence and 
absence of the energy source) (108).  
This technique is sustained by the premise that if the EP is inhibited by potential EPIs 
undergoing evaluation, antibiotics which are extruded by this system and which have 
become ineffective may again be useful (109).  
EtBr is a substrate widely used by bacterial EPs and susceptibility to it in the presence 
and absence of an EPI has been used as a screen for the presence of efflux-related 
resistance mechanisms (31). EtBr emits weak fluorescence in aqueous solution (external 
to the cell) and becomes strongly fluorescent when concentrated in the periplasm (79, 
96) of Gram-negative bacteria and in the cytoplasm of Gram-positive bacteria (96). As 
long as EtBr is not intercalated between nucleic bases of DNA, it is subject to extrusion 
serving as a useful probe. When intercalation into DNA results in a strong binding, it 
precludes EtBr from having access to the EP system of the bacterium (79, 96).  
Accumulation of EtBr inside the cell is the result of the interplay between cell-wall 
permeability and efflux activity. The fluorescence that results from the overall 
intracellular EtBr content is monitored by real-time fluorometry (96). This method 
makes it possible to distinguish accumulation, which reflects the balance between influx 
and efflux, from efflux itself and, therefore, has the potential for the study of the 
kinetics of EtBr transport (79). The determination of the influx and efflux rates of the 
fluorescent substrate EtBr allows the quantification of the cell‘s overall efflux capacity, 
providing useful information to interpret different phenotypes resulting from this 
activity, including multidrug resistance in clinical bacterial strains (79). 
In Figure 5 we can observe a simplified schematic representation of a graphic obtained 
by the fluorescence assay in which a bacterial strain is subjected to the presence and 
absence of a potential EPI. Figures 5B) and 5C) show the influx and efflux of 
fluorescent substrate EtBr by EP AcrAB-TolC when a bacterial strain is subjected to the 





Figure 5 – Accumulation of substrate EtBr in presence and absence of a potential inhibitor of EPs. A) Example 
of a possible graph obtained by the fluorescence assay in which a bacterial strain is subjected to the presence and 
absence of a potential EPI; B) Schematic representation of the accumulation of EtBr in a bacterial cell due to the 
presence of an EPI (rate input > output rate); C) Schematic representation of input and efflux of EtBr in a bacterial 
cell in the absence of an EPI (rate input = output rate); Legend: EPI (efflux pump inhibitor), EtBr (ethidium 






































II. STUDY OBJECTIVES  
 
Active EPs in prokaryotic cells strongly modulate the activity of a large number of 
antibiotics. In order to better understand multidrug resistance and the mechanisms that 
trigger this condition, in this study we intend to expose Salmonella NCTC strain to 
newly synthesized hydantoin compounds in the presence of universal EP substrate EtBr, 
and differences in the accumulation/retention of that substrate by the selected strain in 
the presence of these inhibitory efflux compounds are to be expected. If this takes place, 
we will proceed in exposing in vitro-derived ciprofloxacin-resistant mutants Salmonella 
104-CIP and Salmonella 5408-CIP, induced to high level resistance by step-wise 
exposure to this antibiotic and over-expressing EPs, to all the compounds that have 
favorable results. This way, we can observe if the compounds are indeed effective 
efflux inhibitors when in the presence of strains with induced resistance by 
overexpression of efflux pumps.  
 
In addition to the evaluation of newly synthesized hydantoin compounds, this study will 
also focus on the importance of specific ions involved in the biochemical and 
bioenergetic processes involved in active efflux, i.e., in calcium. The hydantoin group 
of compounds is known to be very effective in the modulation of ion-driven eukaryotic 
EPs and the calcium ion has a fundamental role in the inhibitory effect of hydantoin 
compounds on efflux pumps activity in eukaryotic cells. Therefore, to better understand 
its influence in the modulation of efflux activity in prokaryotic cells we proceeded to 
evaluate the accumulation/efflux of EtBr, using the model Enterobacteriaceae 
Escherichia coli, when in the presence of a calcium channel inhibitor – CPZ, and in the 
presence of a Ca2+ chelator – EDTA. By understanding the role of different ions in the 
biochemical and bioenergetics involved in active efflux, this will allow us to select 
more effective compounds when exposed to specific physiological conditions and a 
better understand of the biochemical conditions necessary for the efficient activity of 




Studied the effect of calcium ions for bacterial transport channels and the activity of 
ATPases enzymes, the role of Ca
2+
 in the extrusion of efflux pump substrate EtBr, under 
challenging physiological conditions, will also be investigated.  
 
Given the present concern over the lack of new antibiotics and the emergence of 
pathogens that have acquired resistance to multiple antibiotics causing infections that 
are effectively untreatable, there is an urgent necessity to identify clear targets to block 
efflux mechanisms and to design specific and more potent inhibitors with minimal 
adverse effects. Combination therapy which allows the administration of both 
antibacterial agents and EPIs may prevent the emergence of resistant Enterobacteriaceae 





III. MATERIAL AND METHODS  
1. Assessment of the role of synthesized hydantoin derivates in various Salmonella 
enterica strains 
1.1. Materials 
1.1.1. Bacterial Strain 
Wild-type strain Salmonella enterica serovar Enteritidis NCTC 13349 was kindly 
provided by Professor Seamus Fanning (School of Agriculture, Food Science, and 
Veterinary Medicine, UCD Veterinary Sciences Centre, University College Dublin, 
Dublin, Ireland). 
Ciprofloxacin-resistant Salmonella enterica mutant strains 104-CIP and 5408-CIP, 
originated from Salmonella enterica serovar Enteritidis 104 and 5408 strains, were also 
provided by Professor Seamus Fanning (77). Salmonella enterica serovar Enteritidis 
104 was exposed to increasing concentrations of ciprofloxacin (0.25, 0.5, 1, 2, 4, 8 and 
16 mg/L) by conducting seven serial passages on tryptone soy agar (Oxoid, Hampshire, 
United Kingdom). The plate with the highest concentration that contained colonies was 
sub-cultured five times on antibiotic-free medium before antibiotic sensitivities were 
determined. The same protocol was conducted for Salmonella enterica serovar 
Enteritidis 5408 (77). 
1.1.2. Culture media, compounds and solutions 
The composition and preparation method of culture media and solutions used 
throughout the assays are described in Tables II and III. 
Table II – Composition of culture media. 





300 g of dried beef infusion; 17.5 g of hydrolyzed casein; 1.5 g 
starch; 4.347 mg Ca
2+
; 6.206 mg Mg
2+







MHB; 17 g of agar 
(1)
; pH 7.3 ± 0.1 a 25ºC 
(1) Oxoid Ltd., Basingstoke, England; (a) autoclaved at 121ºC for 20 minutes at 1 bar in sterile test tubes and stored at 
4ºC; (b) autoclaved at 121ºC for 20 minutes at 1 bar, distributed in sterile plates and stored at 4ºC. 
 
Table III – Composition and preparation method of the solutions used throughout the assays. 
Stock Solutions Composition and preparation 
Phosphate buffered 
saline (PBS) 1X  
(1, a)
 
One tablet dissolved in 200 mL of double distilled water that 
contains 10 mM of phosphate buffer, 2.7 mM of potassium 
chloride and 137 mM of sodium chloride.  
Glucose (Glu) 
(1,b)
 0.2 g/mL in sterile double distilled water. 
(1) Sigma Aldrich, St. Louis, USA; (a) autoclaved at 121ºC for 20 minutes at 1 bar and stored at room temperature; (b) 
after preparing the solution, it was filtered with a polyvinylidene fluoride (PVDF) syringe filter (0.22μm pore size) 
from Rotilabo® (Spritzenfilter Steril, Karlshure, Germany) and stored at -20°C.  
 
The composition and preparation method of antibiotic ciprofloxacin, EP inhibitor TZ 
and all hydantoin derivatives undergoing evaluation are described in Table IV. 
 
Table IV – Composition and preparation method of antibiotic ciprofloxacin, EPI TZ and hydantoin derivatives. 
Stock Solutions Composition and preparation 
Hydantoin derivates 
(a)





 10 mg/mL in sterile double distilled water with addition of 
HCl 
(1)
 until completely dissolved. 
Thioridazine 
(3, b)
 10 mg/mL in sterile double distilled water. 
(1) Merck, Darmstadt, Germany; (2) Fluka Analytical, St. Louis, USA; (3) Sigma Aldrich, St. Louis, USA; (a) after 
preparation, all solutions were stored at -20°C; (b) after preparing the solution, it was filtered with a PVDF Syringe 
filter (0.22μm pore size) from Rotilabo® (Spritzenfilter Steril, Karlshure, Germany) and stored at -20°C. 
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All hydantoin derivatives were kindly provided by Dr. Jadwiga Handzlik and Prof. Dr. 
Katarzyna Kiec-Kononowicz from the Department of Technology and Biotechnology of 
Drugs, Medical College, Jagiellonian University, Cracow, Poland. These potential EPIs 
were evaluated for effects on the EP system of Salmonella enterica NCTC 13349. 
Table V describes the composition and preparation method of universal EP substrate 
ethidium bromide (EtBr) used throughout the various fluorometric assays performed. 
 
Table V – Composition and preparation method of substrate EtBr used by bacterial EPs. 





1 mg/mL in sterile double distilled water, from an initial stock 
concentration of 50 mg/ml, protected from light and stored at 
4ºC. 
(1) Sigma Chemical Co., St. Louis, USA 
 
1.2. Methods 
1.2.1. Cultivation of bacterial strains Salmonella NCTC 13349 and ciprofloxacin-
resistant Salmonella mutant’s 104-CIP and 5408-CIP for MIC determinations 
Wild-type strain Salmonella enterica serovar Enteritidis NCTC 13349 and 
ciprofloxacin-resistant Salmonella enterica serovar Enteritidis mutant‘s 104-CIP and 
5408-CIP were cultivated in simple MHA, in MHA containing 4 mg/L of ciprofloxacin, 
and in MHA containing 16 mg/L of ciprofloxacin, respectively. All MH agar plates 
were incubated over-night at 37ºC. 
Afterward, isolated colonies from the MHA plates containing Salmonella enterica 
NCTC 13349, Salmonella enterica mutant 104-CIP and 5408-CIP were transferred to 
test tubes containing 5 mL of MH broth and MH broth supplemented with 4mg/L and 
16 mg/L of ciprofloxacin, respectively. All test tubes were incubated over-night at 37ºC 
in constant agitation (180 rpm) by the Thermo Scientific MaxQ 4000 (Iowa, USA). 
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Stocks from each one of the cultures in liquid medium were prepared in cryovials by 
adding 10% (v/v) glycerol (JT Baker, Philipsburg, USA) and kept at -80°C in the 
Nuaire Ultralow Freezer (Plymouth, Minnesota, USA). 
 
1.2.2. Cultivation of bacterial strains for the fluorometric accumulation assays 
Isolated colonies from the MHA plates containing Salmonella enterica NCTC 13349 
and ciprofloxacin-resistant Salmonella mutant‘s 104-CIP and 5408-CIP (described in 
section 1.2.1.) were transferred to test tubes containing 10 mL of MH broth and grown 
at 37ºC under constant agitation (180 rpm) (Thermo Scientific MaxQ 4000, Iowa, 
USA), until each culture reached an optical density (OD) of 0.6 transmittance at 600nm 
(Thermo Scientific SPECTRONIC 20D+ spectrophotometer, Fisher Scientific). 
 
1.2.3. Determination of the MIC for Salmonella enterica NCTC 13349 reference 
strain in the presence of hydantoin derivatives, EtBr, TZ and DMSO 
The minimum inhibitory concentration (MIC) is the primary test to determine the 
sensitivity of a bacterium to different compounds under study (100). 
Before each MIC determination, fresh bacterial strains of Salmonella enterica NCTC 
13349 were prepared according to protocol described in section 1.2.1.  
Table VI indicates the concentration of the stock solutions and the concentration range 
used to determine the MIC value for all hydantoin compounds under study, for substrate 
EtBr and for the control EPI TZ. The MIC was defined as the lowest concentration of 
compound for which no bacterial growth was observed (79).  
Concerning the solvent used, instead of setting a range of concentrations, we tested the 
exact amount of DMSO that would be used in all fluorometric assays, and thus verify 
directly if the percentage employed would inhibit bacterial growth. 
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Table VI – Range of concentrations used in determining the MIC for hydantoin compounds, for EtBr and for TZ. 
Evaluation of the effect of 10% of DMSO. 








10 mg/mL 240 – 0.469 mg/L 
EtBr 10 mg/mL 256 – 0.5 mg/L 
DMSO 100% 10% 
TZ 10 mg/ml 256 – 0.5 mg/L 
 
The MICs for all compounds undergoing evaluation, i.e., the hydantoin derivatives, 
substrate EtBr and phenothiazine TZ were determined by the broth microdilution 
method in 96-well microtitre plates according to the Clinical and Laboratory Standards 
Institute (CLSI) guidelines (113).  
In this MIC determination four test controls were performed: (a) MHB sterility test, (b) 
bacterial growth control (MHB and the bacterial strain under study), in order to evaluate 
bacterial viability, (c) solvent control (MHB containing solvent at the same 
concentration as the compounds, and the bacterial strain), to ensure that the solvent has 
no inhibitory effect on bacterial growth, and (d) compound control (MHB and 
compound) to assess turbidity that may interfere in the reading of results.  
From the test tube containing Salmonella enterica NCTC 13349 that was placed in an 
over-night growth (described in section 1.2.1.), a bacterial suspension was prepared in 
10 mL of PBS 1X by adjusting turbidity to 0.5 in the McFarland scale. Aliquots of 0.02 
mL of bacterial suspension were transferred to each well of the 96-well microtitre plate 
(with the exception of the well used for the sterility test and compound control) that 
contained each compound at different concentrations obtained by serial dilutions in 
MHB. The microplates were incubated at 37°C and the MICs results observed after 16 
and 18 hours.  
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For the DMSO measurement, the solvent was added to a well containing MHB and 0.02 
mL of the bacterial suspension in order to obtain a final percentage of 10%. This 
percentage corresponds to the ratio used in fluorometric assays. 
After the incubation period, each assay was validated by the presence of growth in the 
well used for the bacterial growth control (positive control) and no growth in the well 
used for the MHB sterility test (negative control). The other controls were utilized for 
comparison purposes, facilitating the reading of the results. All MICs were performed in 
triplicate for each compound to ensure that the results obtained were consistent.  
In this assay it is important to emphasize some key points. It is essential to monitor and 
evaluate carefully the solvent control, since it may be responsible for inhibiting bacterial 
growth and lead to inaccurate observations that influence the MIC values of the 
hydantoin compounds. 
In order to assure that the inhibitory effect of the compounds against active efflux by 
Salmonella enterica did not compromise cellular viability and the growth rate of the 
bacterium, the concentrations used in the following work did not exceed half the MIC 
value (53, 79).  
 




After determining the MIC values, all compounds were tested in the Real-Time Thermal 
Cycler Rotor-Gene 
TM
 3000 to observe their behavior in the presence of universal efflux 
substrate EtBr and glucose as the immediate source of energy. To quantify the amount 
of relative fluorescence emitted by EP substrate EtBr when accumulated in a specific 
bacterial strain, a semi-automated fluorometric method, standardized in the Group of 
Micobacteria of the Unit of Microbiology of the IHMT/UNL, was utilized. 
As mentioned earlier, this method which employs the Rotor-Gene 
TM
 3000 thermo 
cycler (Corbett Research, Australia) and uses EtBr as the fluorescent probe, which emits 
a weak fluorescence in aqueous solution, but becomes strongly fluorescent within the 
periplasm. This occurs due to its ability to bind to cellular components, making it 
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possible to distinguish accumulation from efflux itself (79), under varying physiological 
conditions, such as pH, presence/absence of an energy source and presence of EPIs 
(108). The instrument also allows the selection of the excitation and emission 
wavelengths that for EtBr are 530 nm band-pass (bp) and 585 nm high-pass (hp) filters, 
respectively (79).  
 
1.2.4.1. EtBr accumulation assay to assess the effect of hydantoin derivatives in 
Salmonella enterica NCTC 13349 
Bacterial growth. As previously elucidated in section 1.2.2., Salmonella enterica 
NCTC 13349 was grown in MHB until it reached an optical density (OD) of 0.6 at 
600nm of transmittance, which corresponds to the exponential growth phase (i.e., mid-
log phase), measured by the Thermo Scientific SPECTRONIC 20D+ spectrophotometer 
(Fisher Scientific). 
Cells were collected in aliquots of 1 mL and centrifuged at 13.000 rpm for 3 minutes at 
room temperature in a mini-centrifuge (Biofuge Pico Heraeus, Kendro Laboratory 
Products, Osterode, Germany). They were washed in PBS 1X pH 7.4 (preparation 
described in Table III), the pellet re-suspended and centrifuged again. This process was 
repeated twice. Then, by adding the same buffer, the OD was adjusted to 0.6 
transmittance at 600nm by the PU8620 UV/VIS/NIR spectrophotometer (Philips, 
Cambridge, United Kingdom), allowing the assay to run with a 0.3 absorbance value 
which corresponds to the optimal cellular concentration set to run in the Rotor-Gene 
TM
 
3000 thermo cycler. 
 
Determination of the optimal concentration of substrate EtBr. To determine the 
optimal concentration of EtBr that could be utilized in the fluorometric assays that 
follow, in order to evaluate the behavior of the hydantoin compounds, a single assay 
was conducted where Salmonella enterica NCTC 13349 strain was subjected to the 
presence of increasing concentrations of EtBr with and without glucose. 
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For this, various ―work solutions‖ of 1 mL containing EtBr (Table V) to yield final 
concentrations of 0.5, 1, 2, 3, and 4 mg/L with and without glucose (Table III) at 0.4% 
were prepared. The volume was adjusted with the addition of PBS 1X at pH 7.4. 
After preparing all solutions and adjusting the cellular OD to 0.6 at 600nm of 
transmittance, aliquots of 0.05 mL of each ―work solution‖ were transferred to 0.2 mL 
tubes containing 0.05 mL of bacterial cells in PBS 1X pH 7.4. They were incubated in 
the thermocycler for 60 cycles at 37ºC to quantify the amount of relative fluorescence 
emitted by different concentrations of EtBr in Salmonella enterica NCTC 13349. 
 
Solution preparation. A ―work solution‖ of 1 mL containing EtBr (Table V) and 
glucose (Table III) was prepared in order to counter final concentrations of 1 mg/L and 
0.4%, respectively. The volume was adjusted with the addition of PBS 1X at pH 7.4. 
Hydantoin compounds were prepared separately, allowing us to control and limit the 
amount of DMSO in each test tube. From the 10 mg/mL stock solutions in DMSO 
(Dimethyl sulfoxide) (Table IV), intermediate solutions were prepared in order to yield 
final concentrations of 120 mg/L and 80 mg/L in the RotorGene test tubes. 
After preparing all solutions and adjusting the cellular OD, aliquots of 0.045 mL of the 
―work solution‖ and 0.01 mL of the compound intermediate solutions were transferred 
to 0.2 mL tubes containing 0.045 mL of bacterial cells in PBS 1X pH 7.4. They were 
incubated in the thermocycler for 60 cycles at 37ºC to quantify the amount of relative 
fluorescence emitted by EtBr when it accumulates in Salmonella enterica NCTC 13349. 
Once again, several controls were prepared and run in parallel with the compounds 
under study. Each assay contained the following controls: EtBr plus compound (1mg/L 
of EtBr and hydantoin compound), solvent control (1mg/L of EtBr, 0.4% of glucose, 
bacterial strain and DMSO), EtBr control (1mg/L of EtBr, 0.4% of glucose and bacterial 
strain). The EtBr plus compound control is further explained in section 1.2.4.2., which 
corresponds to the auto-fluorescence assays. 
From the real-time data, the activity of the compound, namely the relative final 
fluorescence (RFF) of the last time point (minute 60) of the EtBr accumulation assay 




The RF treated value is equivalent to the relative fluorescence (RF) at the last time point 
of EtBr retention curve in the presence of an inhibitor. The RF untreated value refers to the 
relative fluorescence at the last time point of EtBr retention curve of the untreated 
control having the solvent control (DMSO). As shown in Figure 6, the value obtained at 
point 60 in the presence and absence of an EPI is utilized in order to calculate the value 
of RFF. 
 
Figure 6 – Schematic representation of the fluorescence values selected to calculate the RFF value. The blue 
point represents the fluorescence value obtained after 60 minutes in the presence of a potential EPI, whereas the red 
point represents fluorescence value obtained after 60 minutes in the absence of EPI, i.e., the control assay. 
 
The greater the difference between RF treated and RF untreated, the greater the degree of 
EtBr accumulation and therefore, the greater the degree of inhibition of the EP system 
of the bacterium promoted by the agent and its concentration.  
All experiments were repeated three times and the RFF values presented are the average 
of three independent assays. 






1.2.4.2. Auto-fluorescence assay 
In respect to the hydantoin derivatives, the only information we possess is their 
molecular weight and chemical formula. Therefore, we evaluated all the compounds for 
possible self-fluorescence properties that could interfere in the fluorescence assays. 
Thus, 0.01 mL of the intermediate solutions of each hydantoin compound were 
transferred to 0.2 mL tubes containing 0.09 mL of PBS 1X plus EtBr at 1mg/L. This 
was performed for both concentrations tested in each compound. All 0.2 mL tubes were 
placed in RotorGene and testing was done under the same conditions previously 
described. The auto-fluorescence values were subtracted from the values obtained in the 
EtBr accumulation assays performed by Salmonella NCTC 13349, outlined above. 
 
1.2.5. Determination of MIC for two ciprofloxacin-resistant Salmonella mutant 
strains in the presence of hydantoin compound SZ-7, ciprofloxacin and TZ 
Hydantoin compounds that presented cumulative effects in the fluorometric assays 
(described in section 1.2.4.1) were submitted to a new MIC determination, but this time 
in the presence of ciprofloxacin using ciprofloxacin-resistant Salmonella 104-CIP and 
5408-CIP mutant strains.  
The MIC determination between SZ-7 and ciprofloxacin allows us to verify if the 
compound is capable of reducing the MIC of ciprofloxacin in both Salmonella mutants 
strains. By comparing the MIC of ciprofloxacin plus SZ-7 with the MIC of 
ciprofloxacin alone we can verify if the compound possesses a synergistic effect when 
associated with ciprofloxacin.  
The MIC value for TZ was also determined for both ciprofloxacin-resistant strains, in 
the presence and absence of ciprofloxacin. This determination will make it possible to 
compare the hydantoin compound to TZ, a very well known and studied EPI. 
For these assays, quinolone-resistant mutant´s Salmonella 104-CIP and 5408-CIP were 
cultivated in MHA and MHB, according to the protocol described in section 1.2.1. All 
of the following assays were performed using the broth microdilution method in 96-well 
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microtitre plates according to the Clinical and Laboratory Standards Institute (CLSI) 
guidelines (113).  
After performing point 1.2.1., separate MICs determinations were done for 
ciprofloxacin, SZ-7 (hydantoin compound) and phenothiazine TZ by Salmonella 104-
CIP and 5408-CIP. The protocol used for these assays is similar to the one previously 
described in section 1.2.3. Below, Table VII indicates the range of concentrations used 
for each compound to determine the respective MIC value. 
 
Table VII – Range of concentrations used for the MIC determinations of ciprofloxacin, hydantoin derivative SZ-7 
and phenothiazine TZ. 
Bacterial Strain Compounds 







ciprofloxacin 10 mg/mL 240 – 0.469 mg/L 
SZ-7 (hydantoin 
derivative) 
10 mg/mL 240 – 0.469 mg/L 
TZ 10 mg/mL 256 – 0.5 mg/L 
 
Subsequently, the MIC values for both Salmonella 104-CIP and 5408-CIP in the 
presence of both ciprofloxacin and SZ-7 were evaluated. This time, the range of 
concentrations used for ciprofloxacin was between 256 – 0.5 mg/L, while SZ-7 yielded 
final concentrations of 50 and 100 mg/L.  
Again, in 10 mL of PBS 1X solution the bacterial cultures turbidity was adjusted to 0.5 
McFarland scale. Aliquots of 0.02 mL of bacterial suspension and 0.005 mL of SZ-7 
were transferred to each well of the 96-well microtitre plate that contained ciprofloxacin 
distributed by serial dilutions in MHB, in order to respect the range of concentrations 
above referenced. The microplate was incubated at 37°C and the MIC results observed 
after 16 and 18 hours. Regarding to the amount of SZ-7, only 0.005 mL were 
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transferred to avoid precipitation and to decrease the amount of solvent capable of 
inhibiting bacterial growth, while maintaining concentrations of 50 and 100 mg/L. 
For these determinations, the controls used and the validation method are equivalent to 
those described previously in section 1.2.3. 
 
1.2.6. Fluorometric assay to assess the effect of SZ-7 on the accumulation of EtBr 
in two ciprofloxacin-resistant Salmonella mutant strains 
After determining the MIC values, hydantoin derivative SZ-7 and phenothiazine TZ 
were tested in the Real-Time Thermal Cycler Rotor-Gene 
TM
 3000 to examine their 
behavior in the presence of universal efflux substrate EtBr and glucose as the source of 
metabolic energy, by two ciprofloxacin-resistant Salmonella mutant strains. 
1.2.6.1. Accumulation protocol of EP substrate EtBr 
Bacterial growth. As pointed out in section 1.2.2., Salmonella 104-CIP and 5408-CIP 
were grown in MHB until they reached an optical density (OD) of 0.6 at 600nm of 
transmittance (Thermo Scientific SPECTRONIC 20D+ spectrophotometer, Fisher 
Scientific). 
Cells were collected in aliquots of 1 mL and centrifuged at 13.000 rpm for 3 minutes at 
room temperature in a mini-centrifuge (Biofuge Pico Heraeus, Kendro Laboratory 
Products, Osterode, Germany). Cells were washed in PBS 1X pH 7.4, the pellet re-
suspended and centrifuged again. This process was repeated twice. Then, the OD was 
adjusted to 0.6 transmittance at 600nm (PU8620 UV/VIS/NIR spectrophotometer, 
Philips, Cambridge, United Kingdom) using the same buffer. 
 
Determination of the optimal concentration of substrate EtBr. A single fluorometric 
assay was performed using two ciprofloxacin-resistant Salmonella mutant strains in the 
presence of various concentrations of EtBr, in order to select the substrate‘s optimal 
concentration of accumulation and efflux. The protocol utilized is analogous to the one 
elucidated in section 1.2.4.1. 
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Solution preparation. Different ―work solutions‖ of 1 mL were prepared: a tube with 
EtBr and a tube with EtBr and glucose. EtBr and glucose were prepared in order to 
counter final concentrations of 1 mg/L and 0.4%, respectively. Final volumes were 
adjusted by adding PBS 1X at pH 7.4. 
Again, hydantoin derivative SZ-7 was prepared separately, allowing us to control and 
limit the amount of DMSO in the test tube. From the 10 mg/mL stock solutions, 
intermediate solutions of the derivative were prepared in order to yield final 
concentrations of 120 mg/L and 80 mg/L.  
To maintain consistency among the assays, TZ was also prepared separately. Using a 
stock solution of 10 mg/ml, an intermediate solution was prepared utilizing bi-distilled 
sterile water, in order to achieve final concentrations of 64 and 128 mg/L. 
After preparing all solutions and adjusting the cellular OD, aliquots of 0.045 mL of the 
―work solutions‖ and 0.01 mL of the compound intermediate solutions (whether it be 
SZ-7 or TZ) were added to 0.2 mL tubes containing 0.045 mL of cells in PBS 1X pH 
7.4. They were incubated in the thermocycler for 60 cycles at 37ºC to quantify the 
amount of relative fluorescence emitted by EtBr when accumulated in Salmonella 104-
CIP and 5408-CIP mutant strains. 
Several controls were prepared and run in parallel with the compounds under study. 
Each assay contained the following controls: EtBr control (1mg/L of EtBr with and 
without 0.4% of glucose and bacterial strain), and EtBr plus compound control (1mg/L 




2. Assessment of the role of calcium in E. coli reference strain, in the presence of 
chlorpromazine and ethylenediaminetetraacetic acid. 
2.1. Materials 
2.1.1. Bacterial Strain 
Wild-type strain E. coli AG100 (K-12 argE3 thi-1 rpsL xyl mtl Δ(gal-uvrB) supE44), 
which contains an AcrAB-TolC efflux system intact and functional (74).  
2.1.2. Culture media, compounds and solutions 
The composition and preparation method of culture media, compounds and solutions 
used throughout the assay are described in Tables VIII to X. However, the composition 
and preparation method of culture media MHB and MHA, and universal EP substrate 
EtBr were previously described in Tables II and V, respectively. 
 
Table VIII – Composition of culture media. 
Culture Media Composition (per liter of double distillated water) 
Luria Bertani (LB) 
(a)
 10 g casein peptone 
(1)
; 5 g yeast extract 
(1)




Luria Bertani agar (LA)
 (b)
 LB; 20 g of agar 
(3)
 
(1) Merck, Darmstadt, Germany; (2) Panreac Química, Barcelona, Spain; (3) Oxoid Ltd., Basingstoke, England; (a) 
autoclaved at 121ºC for 20 minutes at 1 bar in sterile test tubes and stored at 4ºC; (b) autoclaved at 121ºC for 20 
minutes at 1 bar, distributed in sterile plates and stored at 4ºC. 
 
Table IX – Composition and preparation method of the solutions. 
Stock Solutions Composition and preparation 
PBS 1X, pH 8 
(1, a)
 One tablet dissolved in 200 mL of double distilled water that 
contains 10 mM of phosphate buffer, 2.7 mM of potassium 
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chloride and 137 mM of sodium chloride.   
The pH of 1X PBS at pH 7.4 was adjusted to pH 8 by adding a 
solution of sodium hydroxide (NaOH) 
(2)
. Measurements were 
performed by the Metrohm pH-Meter 632 (Herisan, Switzerland). 
Glucose 
(1,b)





50 mM and 100 mM in double distilled sterile water 
(1) Sigma Aldrich, St. Louis, USA; (2) Merck, Darmstadt, Germany; (a) autoclaved at 121ºC for 20 minutes at 1 bar and 
stored at room temperature; (b) after preparing the solution, it was filtered with a PVDF syringe filter (0.22μm pore 
size) from Rotilabo® (Spritzenfilter Steril, Karlshure, Germany) and stored at -20°C.  
 
Table X – Composition and preparation method of ATPase inhibitor CPZ and Ca2+ chelator EDTA. 
Stock Solutions Composition and preparation 
Chlorpromazine (CPZ) 
(1,a)






Prepared in double distilled water, under constant 
agitation with addition of NaOH 
(2)
 until completely 
dissolved (around pH 8) 
(1) Sigma Aldrich, St. Louis, USA; (2) Merck, Darmstadt, Germany; (a) after preparing the solution, it was filtered with 
a PVDF syringe filter (0.22μm pore size) from Rotilabo® (Spritzenfilter Steril, Karlshure, Germany) and stored at -
20°C; (b) autoclaved at 121ºC for 20 minutes at 1 bar and stored at room temperature. 
 
2.2. Methods    
2.2.1. Cultivation of bacterial strain E. coli AG100 for MIC determinations 
Wild-type strain E. coli AG100 was cultivated in MHA plates and incubated over-night 
at 37ºC. Isolated colonies were then transferred to 5 mL of MHB and incubated over-
night at 37ºC under constant agitation (180 rpm) by the Thermo Scientific MaxQ 4000 
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(Iowa, USA). Stocks of the cultures were made according to the protocol elucidated in 
section 1.2.1. 
  
2.2.2. Cultivation of bacterial strain E. coli AG100 for the fluorometric 
accumulation and efflux assays 
Wild-type E. coli K-12 AG100 strain was cultivated in LA (incubated over-night at 
37ºC) and isolated colonies were transferred to 10 mL of LB (incubated at 37ºC under 
constant agitation by the Thermo Scientific MaxQ 4000 (Iowa, USA)). Again, stocks of 
the cultures obtained in liquid medium were prepared according to the protocol 
described in section 1.2.1. 
 
2.2.3. Determination of MIC for E. coli AG100 reference strain in the presence of 
CPZ, EDTA and EtBr 
Before each MIC determination, fresh bacterial strains were prepared in accordance 
with protocol described in section 2.2.1.  
Below, Table XI indicates the concentration of the stock solutions and the concentration 
range used to determine the MIC values for Ca
2+
 channel inhibitor CPZ, Ca
2+
 chelator 
EDTA and efflux substrate EtBr. Again, the MIC was defined as the lowest 
concentration in which no bacterial growth was observed (79).  
 
Table XI – Range of concentrations used for the MIC determination of CPZ, EDTA and EtBr. 
Bacterial 
Strain 




E. coli  
AG100 
CPZ 10 mg/mL 320 – 0.63 mg/L 
EDTA 0.5 M 160 – 0.31 mM 




The MICs were determined by the broth microdilution method in 96-well microtitre 
plates according to the Clinical and Laboratory Standards Institute (CLSI) guidelines 
(113). In every MIC assay four test controls were made, as explained previously in 
section 1.2.3. 
Briefly, a bacterial suspension was prepared by adjusting the turbidity to 0.5 according 
to the McFarland scale in PBS 1X pH 8. Aliquots of 0.02 mL of bacterial suspension 
were transferred to each well of the 96-well microtitre plate (with the exception of the 
well used for the sterility test and compound control) that contained each compound at 
different concentrations obtained by serial dilutions (MH broth and compound). The 
microplates were incubated at 37°C and the MICs results observed after 16 and 18 
hours.  
The validation and control points are equivalent to the ones used in section 1.2.3. 
 




After determining the MIC values for CPZ, EDTA and EtBr, these compounds were 
analyzed with the aid of the Real-Time Thermal Cycler Rotor-Gene 
TM
 3000 to observe 
their behavior in the presence of varying concentrations of calcium, of glucose as the 
immediate source of energy, and at pH 8. 
2.2.4.1. Accumulation protocol of EP substrate EtBr 
Bacterial growth. As pointed out in section 2.2.2, E. coli AG100 was grown in LB 
until it achieved an OD of 0.6 at 600 nm of transmittance (Thermo Scientific 
SPECTRONIC 20D+ spectrophotometer, Fisher Scientific).  
Cells, collected in aliquots of 1mL, were washed, re-suspended and centrifuged for 3 
minutes at 13,000 rpm (Heraeus Biofuge Pico, Osterode, Germany). This process was 
repeated twice in PBS 1X pH 8 (preparation method described in Table IX). Then, by 
adding PBS 1X pH 8, the OD was adjusted to 0.6 at 600nm (PU8620 UV/VIS/NIR 
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spectrophotometer, Philips, Cambridge, United Kingdom), allowing the assay to run 
with a 0.3 absorbance value. 
Determination of the optimal concentration of substrate EtBr. A single fluorometric 
assay was performed using E. coli AG100 reference strain in the presence of various 
concentrations of EtBr, in order to select the substrate‘s optimal concentration of 
accumulation and efflux. The protocol utilized is analogous to the one elucidated in 
section 1.2.4.1. 
 
Solution preparation. All solutions were prepared in eppendorfs with a final volume of 
1mL. Then, 0.05 mL of each solution was transferred to 0.2 mL microtubes, followed 
by the addition of 0.05 mL of the bacterial suspension previously washed and adjusted 
to 0.6 at 600 nm of transmittance. 
For each test tube different experimental conditions and controls were prepared, as 
described below. 
• 0.05 mL of a solution containing PBS 1X pH 8 and EtBr at 2 mg/L; and 0.05 mL of 
PBS at pH 8 
• 0.05 mL of a solution containing PBS 1X pH 8, 0.8% of glucose and EtBr at 2 mg/L; 
and 0.05 mL of PBS 1X pH 8 
• 0.05 mL of the bacterial suspension; and 0.05 mL of PBS 1X pH 8;  
• 0.05 mL of the bacterial suspension; and 0.05 mL of a solution containing PBS 1X 
pH 8, and 0.8% of glucose;  
• 0.05 mL of the bacterial suspension; and 0.05 mL of a solution containing PBS 1X 
pH 8, 0.8% of glucose and EtBr at 2 mg/L;  
• 5 different solutions: 0.05 mL of the bacterial suspension; and 0.05 mL containing 




• 6 different solutions: 0.05 mL of the bacterial suspension; and 0.05 mL containing 
PBS 1X pH 8, 0.8% of glucose, EtBr at 2 mg/L and calcium chloride to yield 2, 4, 6, 
8, 10 and 20 mM. 
• 6 different solutions: 0.05 mL of the bacterial suspension; and 0.05 mL containing 
PBS 1X pH 8, 0.8% of glucose, EtBr at 2 mg/L, CPZ at 40 mg/L and calcium 
chloride to yield 2, 4, 6, 8, 10 and 20 mM. 
• 6 different solutions: 0.05 mL of the bacterial suspension; and 0.05 mL containing 
PBS 1X pH 8, 0.8% of glucose, EtBr at 2 mg/L and EDTA to yield 2, 4, 6, 8, 10 and 
20 mM. 
• 6 different solutions: 0.05 mL of the bacterial suspension; and 0.05 mL containing 
PBS 1X pH 8, 0.8% of glucose, EtBr at 2 mg/L, EDTA at 10 mM and calcium 
chloride to yield 2, 4, 6, 8, 10 and 20 mM. 
• 6 different solutions: 0.05 mL of the bacterial suspension; and 0.05 mL containing 
PBS 1X pH 8, 0.8% of glucose, EtBr at 2 mg/L, EDTA at 20 mM, and calcium 
chloride to yield 2, 4, 6, 8, 10 and 20 mM. 
In the Corbett 3000 thermocycler, aliquots with a final volume of 0.1 mL were tested to 
assess the effect of CPZ and EDTA on the accumulation of EtBr with and without the 
modulation effect of Ca
2+
. All test tubes were incubated in the thermocycler at 37ºC and 
fluorescence was measured over a period of 60 cycles (approximately 60 minutes). 
To note, all concentrations in the test tubes correspond to half the concentration in the 
solutions initially prepared. In other words, the test tubes contained EtBr and glucose to 
yield final concentrations of 1 mg/L and 0.4%, respectively, with varying 
concentrations of CPZ (10, 20, 30, 40 and 50 mg/L) with and without varying 
concentrations of Ca
2+
 (1, 2, 3, 4, 5 and 10 mM), and, varying concentrations of EDTA 
(1, 2, 3, 4, 5 and 10 mM) with and without varying concentrations of Ca
2+
 (1, 2, 3, 4, 5 




2.2.4.2. Efflux protocol of EP substrate EtBr 
Protocols regarding bacterial growth and the determination of the optimal concentration 
of substrate EtBr are similar to the ones described in section 2.2.4.1. 
Solution preparation. For this assay, we used the solutions previously prepared in 
eppendorfs with a final volume of 1 mL. Initially, the fluorescence in microtubes 
containing 0.045 mL of bacterial cells in PBS pH 8, no glucose and EtBr to yield a final 
concentration of 1 mg/L was followed for approximately 40 minutes at 37ºC. The 
instrument was paused and 0.045 mL of various solutions undergoing evaluation were 
added, namely: PBS pH 8 alone, PBS pH 8 containing glucose to yield a final 
concentration of 0.4%, PBS pH 8 containing 0.4% of glucose with varying 
concentrations of CPZ, PBS pH 8 containing 0.4% of glucose with varying 
concentrations of CPZ in combination with varying concentrations of Ca
2+
, PBS pH 8 
containing 0.4% of glucose with varying concentrations of EDTA, PBS pH 8 containing 
0.4% of glucose with varying concentrations of EDTA in combination with varying 
concentrations of Ca
2+
. Immediately after adding the solutions, the instrument was 





IV. RESULTS  
1. Assessment of the role of newly synthesized hydantoin derivates in various 
Salmonella enterica strains 
1.1. MIC values obtained for the hydantoin compounds, EtBr and TZ by 
Salmonella enterica NCTC 13349 reference strain 
To be able to evaluate the activity of any agent against EP systems, the concentrations 
tested must correspond to concentrations that do not affect cellular viability and 
replication (108).  
Tables XII and XIII present the MIC values obtained for every hydantoin compound 
under study, for universal efflux substrate EtBr and for EPI thioridazine (TZ) which is 
used as a positive control. Also, outlined below is the result obtained when Salmonella 
enterica serovar Enteritidis NCTC 13349 was submitted to the presence of 10% of 
DMSO, in order to evaluate cellular viability. All assays were repeated three times, in 
order to ensure reproducibility and consistency of results. 
 
Table XII - MIC values obtained by Salmonella enterica NCTC 13349 for substrate EtBr and for TZ. Also, the result 
obtained from the assay used to evidence bacterial growth in the presence of DMSO at 10%. 
Salmonella NCTC 
13349 
DMSO at 10% MIC for EtBr 
(mg/L) 
MIC for TZ 
(mg/L) 







Table XIII – MIC values obtained for all hydantoin derivatives under study by Salmonella enterica NCTC 13349. 
Synthesized Compounds MIC (mg/L) 
(Halogen)phenylpiperazine derivatives of 5-phenylhydantoin 
























N3-alkylamine derivatives of 5,5-diphenylhydantoin (modifications 
of KF-2): 
M-1, M-2, M-3, M-4, Ksc-5and Ksc-7 
> 240 
Halogenphenylpiperazine derivatives of 5-arylidenehydantoin 
(modifications of AD-26): 
AD-38 
(2)
, AD-39, AD-40 
(2)
, AD-42, AD-43, AD-44, AD-45, AD-46 
and AD-49 
> 240 
5-Alkoxyarylidenetiohydantoin (modification of SZ-7): 
HY-42, HY-43, HY-44, HY-46, HY-47, HY-72, HY-73, AM-1, AM-2, 
AM-3 and AM-4 
> 240 
Other hydantoin derivatives: 
SZ-2, SZ-7 
(2)
, LL-9, BS-1, JH-63, MN-3, TD-7k, GG-5k, P3, P7, RW-
15b, AD-26, RW-13, AD-29, KF-2, PDPH-3, Mor-1, XV, Thioam-1, 
JHF-1, JHC-2, JHP-1 and Fur-2 
> 240 
Legend: (1) Heated to dissolve completely; (2) presented precipitation in the microtitre plate, complicating the reading 
of the results. 
 
As shown in Table XIII, due to the fact that the MIC values of all sixty-three hydantoin 
derivatives exceeded 240 mg/L, the sub-inhibitory concentrations employed in the 
fluorometric assays that follow were 80 and 120 mg/L.  
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The MIC value obtained by Salmonella enterica serovar Enteritidis NCTC 13349 for 
EtBr and TZ, presented in Table XII, also provides information as to what sub-
inhibitory concentrations can be used in the semi-automatic fluorometric assays that 
follow. TZ, as is the case of the hydantoin compounds, was used at a quarter and at half 
of the MIC value to guarantee no interference in cellular viability.  
In relation to EtBr, the optimal concentration to use in the fluorometry assays 
corresponds to the concentration at which minimum accumulation is observed. To select 
this concentration, an accumulation assay with Salmonella NCTC 13349 was conducted 
utilizing substrate EtBr at varying concentrations in the presence and absence of glucose 
as an immediate energy source (as shown in Figure 7). 
 
 
Figure 7 – Accumulation of EtBr at varying concentrations by Salmonella enterica NCTC 13349. Accumulation 
of EtBr to yield final concentrations of 0.5, 1, 2, 3, and 4 mg/L in the absence and presence of glucose at 0.4%. 
 
The selected concentration of EtBr was 1 mg/L, since in both assays Salmonella 13349 
presented values of fluorescence below 10% with a slight tendency to accumulate. By 
using this concentration of substrate simultaneously with inhibitory compounds 
































Sal. NCTC + EtBr 0.5 mg/L 
Sal. NCTC + EtBr 1 mg/L 
Sal. NCTC + EtBr 2 mg/L 
Sal. NCTC + EtBr 3 mg/L 
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Time (minutes) 
Sal. NCTC + EtBr 0.5 mg/L + Glu 
Sal. NCTC + EtBr 1 mg/L + Glu 
Sal. NCTC + EtBr 2 mg/L + Glu 
Sal. NCTC + EtBr 3 mg/L + Glu 
Sal. NCTC + EtBr 4 mg/L + Glu 
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since the device is capable of detecting the substrates signal. If we were to use higher 
concentrations of substrate EtBr in the presence of the EPI under study, the fluorescence 
values obtained wouldn‘t be detected by the device since the fluorescence readings are 
limited. 
The selection of the optimal concentration of EtBr to use in the fluorometric assays for 
the remaining strains were chosen based on the same criteria elucidated above. 
 
1.2. Accumulation of EtBr in the presence of various hydantoin derivates in 
Salmonella enterica NCTC 13349 by the fluorometric assay 
Sixty-three hydantoin compounds were evaluated for their efflux modulating effects in 
the intrinsic efflux activity of Salmonella enterica serovar Enteritidis NCTC 13349 by 
using real-time fluorometry. This method that uses fluorescent substrate EtBr provides a 
powerful tool to continuously monitor transport, since EtBr penetrates the bacterial cell 
wall and accumulates in the periplasmic space of Gram-negative bacteria when its 
concentration exceeds the capacity of the EP system (108) or its extrusion by the EP 
system is impaired by an inhibitory agent (74, 107).  
To control and monitor whether hydantoin compounds possess inhibitory effects on EP 
system of Salmonella NCTC strain, an assay was carried out in parallel using TZ as the 
EPI. Given the information regarding this compound and its inhibitory properties on 
several strains, it was used for comparison purposes as a positive control. 
In Figure 8 we can observe the effect that TZ possesses on the accumulation of EtBr by 





Figure 8 – Accumulation of EtBr by Salmonella enterica NCTC 13349 in the presence of varying 
concentrations of TZ. Accumulation of EtBr at 1mg/L in the presence of glucose at 0.4% and TZ to yield final 
concentrations of 32 and 64 mg/L. 
 
As shown in Figure 8, TZ at 64 mg/L (1/2 MIC value) presents a somewhat elevated 
accumulation rate in the beginning of the assay until a gradual steady-state is reached 
and, over time the steady-state between accumulation and efflux of EtBr starts to 
decrease moderately. This data shows that the strain involved, despite enduring the 
inhibitory effects of the EPI at the beginning of the assay, quickly starts to efflux the 
compound that accumulates up to a level that can jeopardize its survival.  
 
1.2.1. Auto-fluorescence assays obtained by the hydantoin derivatives 
Due to the lack of information of the hydantoin derivatives under study, we previously 
confirmed by the fluorometric method if any of the sixty-three compounds presented 
auto-fluorescent properties that could interfere with the results obtained in the 
accumulation assays performed by Salmonella NCTC 13349. 
When assessed by the semi-automatic fluorometric method using wavelengths of 
530/585hp, many compounds presented no auto-fluorescent characteristics, since during 

























Salmonella + TZ 32mg/L + EtBr + Glu Salmonella + TZ 64mg/L + EtBr + Glu 
Salmonella + EtBr + Glu TZ + EtBr + Glu 
EtBr + Glu 
58 
 
In Figure 9 we can observe an example of an auto-fluorescence assay performed for one 
of the sixty-three hydantoin compounds. 
 
 
Figure 9 – Auto-fluorescence assay performed for hydantoin compound SZ-2. Example of an auto-fluorescence 
assay which was performed for all sixty-three compounds at final concentrations of 80 and 120 mg/L, in the presence 
of PBS at pH 7.4 and EtBr at 1 mg/L. 
 
However, not all compounds were exempt from these auto-fluorescent properties. The 
hydantoin compounds marked with a * in the Table that follows (Table XIV) presented 
significant values of auto-fluorescence when the assay was conducted in the presence of 
EtBr at 1mg/L and PBS at pH 7.4 due to a natural quenching-effect between these 
hydantoin derivatives and EtBr. When the assay was then conducted in the absence of 
EtBr, the compounds in question presented no fluorescent properties.  
Thus, these compounds were promptly discarded and were not evaluated due to the fact 
that the auto-fluorescent values obtained were product of the interaction between EtBr 
and the hydantoin compound under evaluation. Even if these compounds possessed 




























SZ-2 80mg/L + EtBr  SZ-2 120mg/L + EtBr  EtBr 
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1.2.2. Relative final fluorescence values obtained by the hydantoin derivatives 
Because of the extremely large number of graphs depicting the effects of sixty-three 
hydantoin compounds at two concentrations in an assay that contained a source of 
metabolic energy (glucose), all results are presented in tabular form. The index of 
activity of two concentrations of each of the sixty-three hydantoin compounds against 
the EP system of the Salmonella enterica NCTC 13349 was calculated with the aid of 
the formula described in section 1.2.4.1. of the Material and Methods. Briefly the 
relative final fluorescence index is a measure of how effective the EPIs inhibitory effect is on 
efflux (at a certain concentration) by comparison of the final fluorescence (after 60 minutes) of 
EtBr + EPI exposed cells against cells exposed only to EtBr (absence of EPI).  
 
Table XIV – Relative final fluorescence (RFF) based on accumulation of EtBr. Accumulation of EtBr at 1 mg/L 
by Salmonella NCTC 13349 in the presence of glucose at 0.4% and PBS pH 7.4. The hydantoin derivatives were 








80 120 80 120 80 120 
SZ-2  -0,09 0,24 JHP-1  -0,21 0,02  Ksc-7  -0,11 -0,20 
SZ-7 3,46 2,62 Fur-2  -0,17 0,04  AD-38  0,01 -0,07 
LL-9  -0,20 0,02  GG-2a  0,44 -0,16  AD-39  0,27 0,03 
BS-1  0,06 -0,01  GG-4a  -0,05 -0,18  AD-40  -0,01 0,03 
JH-63 0,00 0,00  MN-1  -0,44 -0,14  AD-42  0,11 0,13 
MN-3  -0,21 0,58  MN-2  0,01 0,02  AD-43  0,15 0,09 
TD-7k 0,14 -0,07  MN-4  0,18 -0,19  AD-44  0,21 0,14 
GG-5K  -0,54 -0,22  MN-5  -0,02 -0,16  AD-45  0,21 0,48 
P3  -0,18 -0,12  MN-6  -0,05 0,10  AD-46  -0,06 -0,02 
P7  -0,23 -0,06  BS-5  -0,42 -0,14  AD-49  0,09 0,02 
RW-15b  -0,09 0,21  BS-6  -0,16 -0,23  HY-42*  - - 
AD-26  -0,07 -0,13  TN-2  0,04 -0,18  HY-43*  - - 
RW-13  0,14 0,04  TN-3  -0,01 -0,09  HY-44  -0,06 -0,34 
AD-29  -0,20 -0,18  BG-1  -0,15 -0,17  HY-46  -0,43 -0,05 
KF-2  -0,44 -0,04  BG-2  -0,14 -0,23  HY-47* - - 
PDPH-3  -0,36 -0,31  JH-1  -0,20 -0,26 HY-72*  - - 
Mor-1  -0,35 -0,10  M-1  -0,19 -0,23 HY-73  -0,14 -0,29 
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XV  -0,15 -0,23  M-2  -0,11 -0,06 AM-1*  - - 
Thioam-1  1,49 1,83  M-3  0,00 -0,19 AM-2*  - - 
JHF-1  -0,14 -0,36  M-4  -0,22 -0,13 AM-3* - - 
JHC-2  -0,27 -0,14  Ksc-5  -0,15 0,46 AM-4  -0,05 -0,24 
As observed in Table XIV, all compounds besides SZ-7 possess low RFF values. 
Consequently, these compounds were discarded from further evaluation since they most 
likely do not possess inhibitory activity against Salmonella enterica NCTC 13349. 
 
1.2.2.1. Fluorometric assay obtained for hydantoin derivative SZ-7 
As evident in Table XIV, no derivative appeared to present activity against the intrinsic 
EP system of Salmonella enterica serovar Enteritidis NCTC 13349 besides compound 
SZ-7, in the presence of metabolic energy (indicated in Figure 10).   
 
Figure 10 – Accumulation of EtBr by Salmonella enterica NCTC 13349 in the presence of varying 
concentrations of SZ-7. Accumulation of EtBr at 1 mg/L in the presence of glucose at 0.4% and SZ-7 to yield final 
concentrations of 80 and 120 mg/L. The values represent the accumulation of EtBr by Salmonella NCTC subtracted 




























Salmonella + SZ-7 80 mg/L + EtBr + Glu Salmonella + SZ-7 120 mg/L + EtBr + Glu 
Salmonella + EtBr + Glu Salmonella + DMSO   
SZ-7 + EtBr + Glu EtBr + Glu 




As concluded from the data in Figure 10, compound SZ-7 has a valuable inhibitory 
effect on the EP activity of Salmonella NCTC strain and was selected for further 
experiments to test its ability to inhibit efflux of antibiotics in resistant Salmonella 
mutant strains with over expressed efflux activity. 
 
1.3. MIC values obtained for Salmonella mutants 104-CIP and 5408-CIP in the 
presence of ciprofloxacin, hydantoin compound SZ-7, TZ, and EtBr 
Compound SZ-7, which inhibited the efflux of EtBr in reference strain Salmonella 
enterica NCTC 13349, was subsequently employed against two ciprofloxacin-resistant 
Salmonella mutant strains with over-expressed EP activity (77), in the presence of 
increasing concentrations of ciprofloxacin.  
For reasons mentioned earlier, the MIC value for phenothiazine TZ and substrate EtBr 
was also obtained by Salmonella mutant‘s 104-CIP and 5408-CIP.  
 
Table XV – MIC values obtained for antibiotic ciprofloxacin, hydantoin compound SZ-7, phenothiazine TZ and 
substrate EtBr by Salmonella enterica 104-CIP and 5408-CIP. 




Ciprofloxacin 32 32 
SZ-7 > 240 > 240 
Ciprofloxacin    + [SZ-7] = 100 mg/L 
1
 4 0.469 
[SZ-7] = 50 mg/L 
1
 8 8 
Ciprofloxacin    + [SZ-7] = 100 mg/L 
2
 16 0.469 
[SZ-7] = 50 mg/L 
2
 16 16 
TZ  > 256 > 256 
Ciprofloxacin    + [TZ] = 100 mg/L 
2
 8 32 
 [TZ] = 50 mg/L 
2
 32 32 
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EtBr  > 256 128 
Legend: 1 Solvent used was DMSO; 2 Solvent used was sterile bi-distillated water. [SZ-7]: concentration of SZ-7; 
[TZ]: concentration of TZ. 
 
As shown in Table XV, we can verify that the association between ciprofloxacin and 
SZ-7 significantly reduces the MIC value of both ciprofloxacin-resistant strains, when 
comparing to the MIC value obtained in presence of ciprofloxacin alone and the MIC 
value obtained for ciprofloxacin in presence of the positive control EPI (TZ). 
Given the possibility that the solvent utilized could in some way interfere with the 
bacterial growth, for this determination both DMSO and double distilled water were 
used as the solvents for SZ-7. As evident in Table XV, results do reveal that DMSO can 
slightly inhibit the bacterial growth, when comparing to the results obtained using 
double distilled water (one dilution difference). However, in both cases there is a 
decrease in the MIC value, revealing that hydantoin derivative SZ-7 is potential 
candidate as a bacterial EPI with application for the reversal of efflux based quinolone 
resistance in Salmonella. 
1.4. Accumulation of EtBr in the presence of hydantoin derivate SZ-7 in 
Salmonella mutants 104-CIP and 5408-CIP by the fluorometric assay  
After observing the synergistic effect between ciprofloxacin and hydantoin derivative 
SZ-7 on the decrease in the MIC value for ciprofloxacin by Salmonella mutant strains 
with resistance to this class of antibiotics due to the overexpression and activity of EPs 
(77), we proceeded to assess the behavior of these strains by the semi-automated 
fluorometric assay previously described.  
Ciprofloxacin-resistant strains Salmonella 104-CIP and 5408-CIP were submitted to the 
presence of hydantoin compound SZ-7, in order to verify differences in the 
accumulation of substrate EtBr, substrate of their over-expressed EPs. Again, 
fluorescence assays containing phenothiazine TZ were performed in parallel as a 
positive control, allowing the comparison between compounds. 
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1.4.1. Effect of hydantoin derivative SZ-7 on accumulation of EtBr in Salmonella 
mutants 104-CIP and 5408-CIP 
In Figure 11, we can see that SZ-7 has an inhibitory effect on resistant-ciprofloxacin 
mutant strains Salmonella 104-CIP and 5408-CIP; however there is a noticeable 
difference of activity between both strains. 
 
 
Figure 11 – Accumulation of EtBr by Salmonella mutant’s 104-CIP and 5408-CIP in the presence of varying 
concentrations of SZ-7. Accumulation of EtBr at 1 mg/L in the presence of glucose at 0.4% and SZ-7 to yield final 
concentrations of 80 and 120 mg/L. 
 
Hydantoin compound SZ-7 appears to have a more pronounced effect in the 
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1.4.2. Effect of TZ on accumulation of EtBr in Salmonella mutants 104-CIP and 
5408-CIP 
As previously pointed out, TZ tests were performed in parallel to serve as a positive 
control in Salmonella mutant strains 104-CIP and 5408-CIP, since phenothiazine TZ is 
known to have an inhibitory effect against EPs of Gram-negative bacteria (21). 
Figure 12 presents the accumulation of EtBr by ciprofloxacin-resistant mutant‘s 
Salmonella 104-CIP and 5408-CIP, in the presence of sub-inhibitory concentrations of 
TZ and of a source of metabolic energy. 
 
  
Figure 12 – Accumulation of EtBr by Salmonella mutant’s 104-CIP and 5408-CIP in the presence of varying 
concentrations of TZ. Accumulation of EtBr at 1 mg/L in the presence of glucose at 0.4% and TZ to yield final 
concentrations of 64 and 128 mg/L. 
 
As shown in the graphs above, and compared to the results presented in Figure 8 for 
reference strain Salmonella NCTC 13349, TZ has moderate inhibitory effect on the EP 
system of both quinolone resistant mutant strains at the concentrations tested. These 
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derivative SZ-7 possesses on EtBr efflux of both quinolone resistant mutant strains, in 
particular Salmonella 104-CIP.  
Overall these promissing results point towards a similar mechanism of action between 
coumpoud SZ-7 and phenothiazine TZ, with the hydantoin derivative evidencing a 
much more potent inhibitory effect. Since these derivatives were synthesized in Poland 
to be tested as putative EPIs for bacterial and cancer cell EPs (46, 98), their scarcity 
prevented us from further exploring the bioenergetic requirements of the inhibitory 
effect here revealed by compound SZ-7. Since hydantoins and phenothiazines are 
related heterocyclic compounds with similar mecahnisms of action (20, 52, 98), we 
decided to further explore this bioenergetic hypothesis using phenothiazines and E. coli 
as the bacterial model where the bioenergetic environment and requirements are best 




2. Assessment of the role of calcium in E. coli AG100, in the presence of CPZ and 
EDTA 
Since the CPZ inhibitory effect is known to be related to membrane transport channels 
dependent upon calcium ions (Ca
2+
) and ATPases activity, the role of Ca
2+
 as well as 
pH was investigated in order to clarify the affect of these ions on active efflux which 
consequently interferes with the activity of EPIs, in particular the calcium channel 
inhibitors. Previous results obtained by our research group concluded that at pH 5 efflux 
is independent of metabolic energy; however, at pH 8 it is entirely dependent of 
metabolic energy and Ca
2+
 is essential to maintain the activity of the bacterial ATPases 
(5, 52). 
 
2.1. MIC values obtained for E. coli AG100 in the presence of CPZ, EDTA and 
EtBr 
Phenothiazines such as CPZ and thioridazine (TZ) inhibit the binding of Ca
2+
 to 
enzymes involved in supplying energy from the hydrolysis of ATP (2). Therefore, Ca
2+
 
plays a crucial role in cellular signaling, biochemical pathways, membrane transport 
channels and in the activity of certain ATPases (67, 72).  
To be able to evaluate these effects in the semi-automated fluorometric assay, we 
initially determined the MIC values for EPI CPZ, Ca
2+
 chelator EDTA and substrate 
EtBr. The results obtained will provide information as to what concentrations do not 
affect cellular viability and replication (108). The assays were repeated three times, in 
order to guarantee reproducibility of the results obtained.  
 
Table XVI – MIC values obtained by E. coli AG100 in the presence of EPI CPZ, Ca2+ chelator EDTA and substrate 
EtBr. 
E. coli K-12 
AG100 
MIC for CPZ (mg/L) MIC for EDTA (mM) MIC for EtBr (mg/L) 




2.2. Accumulation of EtBr in the presence of CPZ and EDTA to assess the role of 
calcium in E. coli AG100 strain by the fluorometric assay 
Since these phenothiazines have major effects on the accumulation and efflux of EtBr at 
pH 7 (107), and because these effects can be modified by metabolic energy, the role of 
Ca
2+
 in the modulation of EtBr accumulation and efflux was evaluated.  
Because CPZ has a greater outcome on accumulation of EtBr by E. coli AG100 strain 
than other phenothiazines, CPZ was chosen in order to evaluate the role of Ca
2+
. In 
addition, due to the chelating properties of EDTA and its ability to ‗sequester‘ metal 




, this agent was also used to study the role of Ca
2+
 on the 
efflux of EtBr. 
As pointed out previously, this technique provides the ability to continuously monitor 
the transport of substrate EtBr, making it the ideal tool to evaluate accumulation/efflux 
by EP systems (74, 107), when in the presence of diverse physiological conditions. 
 




2.2.1.1. Effect of CPZ at varying concentrations on the accumulation of EtBr 
As expected, Figure 13 confirms that increasing concentrations of calcium channel 
inhibitor CPZ promotes analogous increases in the amount of relative fluorescence, 
which is associated with increased accumulation of EtBr by E. coli AG100 at pH 8, as 





Figure 13 – Effect of chlorpromazine (CPZ) on accumulation of EtBr. EtBr accumulation by E. coli AG100 




 modulation of the effects of CPZ on accumulation of EtBr 
Due to the ability that CPZ has on inhibiting various EP systems by inhibiting the 
transport of Ca
2+
 (56), the potential modulating effect of Ca
2+
 on the activity of CPZ 
was investigated. 
As seen in Figure 14, the activity of CPZ on the accumulation of EtBr can be 
completely abolished by the addition of 5mM of Ca
2+
 to the assay.  
 
Figure 14 – Modulation of the effect of CPZ by calcium ions (Ca
2+
). EtBr accumulation by E. coli AG100 strain 
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This result supports our hypothesis that Ca
2+
 plays a key role in the mechanism by 
which EP systems function in Gram-negative bacteria and strongly modulates the 
activity of Ca
2+ 
channel inhibitors.  
 




2.2.2.1. Effect of EDTA at varying concentrations on the accumulation of EtBr 
To confirm this data, we proceeded in determining if the addition of Ca
2+
 chelator 
EDTA would present similar outcomes when in the presence of Ca
2+
. As seen in Figure 
15, the addition of EDTA to the assay promotes a modest accumulation of EtBr, owing 




Figure 15 – Effect of EDTA on the accumulation of EtBr. EtBr accumulation by E. coli AG100 strain with EtBr at 




 modulation of the effects of EDTA on accumulation of EtBr  
Afterwards, we evaluated if these cumulative effects induced by EDTA could be 
reversed by the presence of Ca
2+
. As shown in Figure 16, Ca
2+
 modulates the effects of 
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accumulation of EtBr. Therefore, the activity of EDTA on the accumulation of substrate 
EtBr can also be abolished by the addition of Ca
2+
 ions to the assay. 
 
 
Figure 16 – Modulation of the effect of 5 and 10 mM of EDTA by Ca
2+ 
ions. EtBr accumulation by E. coli AG100 
strain with EtBr at 1 mg/L, glucose at 0.4%, EDTA at 0.0, 5 and 10 mM, and calcium chloride to yield final 
concentrations of 0.0, 1, 5 and 10 mM. 
 
2.2.3. Effects of CPZ with and without Ca
++
 on efflux of EtBr 
To provide data that indeed it is the EP system that is affected by the presence of EPI 
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Figure 17 – Effects of chlorpromazine (CPZ) with and without Ca
2+
 on efflux of EtBr by E. coli AG100 strain. 
At the beginning of the assay, all tubes accumulated EtBr at 1 mg/L and PBS at pH 8.The addition of glucose at 0.4% 
and CPZ at 25 and 30 mg/L took place at approximately 40 minutes, with and without 5 mM calcium chloride. 
 
The first 35 minutes of the assay which are not presented in Figure 17 served for the 
sole purpose to allow the accumulation of EtBr in the absence of glucose to take place. 
However, as shown in Figure 17, subsequent efflux of EtBr can be strongly modulated 
by the addition of glucose, which accounts for complete efflux for the duration of the 
assay. When glucose and CPZ at two concentrations that do not affect replication of the 
organism are included in the assay, each one inhibits efflux of EtBr in a concentration 
dependent manner. The addition of glucose and Ca
2+
 to the tubes containing CPZ 
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V. DISCUSSION AND CONCLUSION 
 
Bacteria have evolved sophisticated mechanisms of resistance including efficient drug 
EPs that accommodate a wide range of substrates, both antibacterial and non-
antibacterial. Thus, it has become indispensable to optimize the pharmacokinetics and 
pharmacodynamics of antibacterial therapy (42) and develop ideal EPIs that assist 
antibacterial agents in combination therapy. 
The design of effective and selective EPIs requires an extensive screening process that 
involves various compounds, whether they have natural or synthetic origin. With 
respect to hydantoin derivatives, over the past several years researchers have conducted 
studies that explore various aspects of their biochemical and pharmacological 
properties, since these compounds present beneficial physicochemical properties in the 
field of medicine. 
For this particular study, one of the primary objectives focused on assessing possible 
inhibitory effects inherent to sixty-three hydantoin derivatives synthesized in the 
Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian 
University, Cracow, Poland by Dr. Jadwiga Handzlik and Prof. Dr. Katarzyna Kiec-
Kononowicz, on the intrinsic efflux activity of Salmonella enterica serovar Enteritidis 
NCTC 13349. Then, after the screening process, we subjected the most promising 
hydantoin derivatives to the presence of an antimicrobial agent and evaluated their 
behavior, but this time employing ciprofloxacin-resistant mutant strains Salmonella 
enterica 104-CIP and 5408-CIP, two mutant strains with increased expression and 
activity of EPs responsible for a quinolone resistant phenotype. 
In order to do so, two experimental techniques were applied to explore these inhibitory 
properties: a) determination of minimal inhibitory concentrations (MIC) by the 
microdilution method in presence and absence of the modulator and antibiotic, and b) a 
semi-automated real-time fluorometric method, which employs EP substrate EtBr. The 
MIC determinations for all sixty-three compounds in the presence of Salmonella 
enterica serovar Enteritidis NCTC 13349 provided information as to what concentration 
of the compound under study was capable of inhibiting bacterial growth and affecting 
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cellular viability. From this assay we observed that none of the compounds were able to 
inhibit the growth of Salmonella enterica serovar Enteritidis NCTC 13349 at 
concentrations as high as 240 mg/L. As for the control EPI, TZ was also unable to 
inhibit bacterial growth at concentrations as high has 256 mg/L. 
After these determinations, we proceeded in evaluating all sixty-three hydantoin 
compounds by the semi-automated fluorometric method. This method offers the 
possibility to screen a great number of potential EPIs providing information about the 
transport kinetics that take place, in a time-saving, accurate and inexpensive way. By 
detecting the balance between accumulation and efflux of EtBr in a real time basis, it 
provides the possibility to alter certain parameters like temperature and pH at which the 
assay will occur.  
However, other parameters must remain unaffected, since they are essential for the 
proper functioning of the assay and, consequently, in obtaining reliable results. These 
requirements are: i) the concentration of EtBr free in the extracellular environment, the 
concentration of all compounds tested and their solvents must not affect cellular 
viability; ii) the compound and/or its solvent should not interfere with the fluorescence 
signal in the thermocycler; iii) cells should be given the ideal conditions in terms of 
their energy source (glucose at 0.4%), while testing potential efflux inhibitors. This 
ensures that in optimal energy conditions, the inhibitory effect that may be produced on 
efflux is most likely due to the EPI under evaluation.  
Therefore, this study progressed with the assessment of possible auto-fluorescent 
properties of all hydantoin compounds undergoing evaluation, in the presence of EtBr 
that could interfere with the subsequent evaluation of their inhibitory effects against the 
intrinsic EP systems of Salmonella enterica serovar Enteritidis NCTC 13349. All 
compounds that presented these properties were promptly discarded from the study 
since it would not be possible to evaluate their inhibitory behavior using this technique. 
In order to respect the parameters set forth above, all compounds were utilized at half 
and at a quarter of their MIC values, in order to guarantee bacterial viability and the 
capacity to extrude any compound to which they were subjected. 
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EtBr was used at the lowest concentration in which accumulation was observed by 
Salmonella NCTC 13349, to guarantee the minimum fluorescent level representing the 
basal steady-state level between accumulation and efflux of EtBr (steady-state reached 
around 10% of relative fluorescence from the instrument). Thus, when the strain is 
subjected to the presence of hydantoin derivatives and/or antimicrobial agents and the 
abrupt accumulation of EtBr occurs due to efflux inhibition, EtBr accumulates in the 
periplasm and the increased fluorescence is possible to monitor since the fluorescence 
values obtained are within the range of readings of the instrument. Otherwise, if the 
concentration of EtBr used was too high, when subjecting the strain to the inhibitory 
effect of hydantoin compounds and quinolones, it would not be possible to monitor that 
activity, since the fluorescence values obtained would cross over the reading limit of 
device. 
In this assay, the selection of the pH of the medium was approximated to the pH value 
present in interstitial fluids, namely, a pH of 7.4. This way, the in vitro activity of the 
agent against the EP system of a given bacterium provides meaningful results possible 
to correlate to in vivo activity. For this reason, the assays that tested all sixty-three 
hydantoin derivatives by the fluorometry technique were conducted at pH 7.4, in the 
presence of glucose (0.4%) as the source of metabolic energy.  
As for the results obtained, with the exception of compound SZ-7, none of the other 
hydantoin derivatives presented inhibitory activity against the EP system of Salmonella 
enterica serovar Enteritidis NCTC 13349. The only compound capable of enhancing 
EtBr accumulation was derivative SZ-7, in the presence of optimal efflux conditions, 
i.e., in the presence of glucose and a pH of 7.4. 
Given the results obtained in the semi-automated fluorometric assay, we re-assessed 
compound SZ-7, in order to demonstrate its effectiveness. With this intent, we used 
induced ciprofloxacin-resistant mutants Salmonella enterica serovar Enteritidis 104-CIP 
and 5408-CIP with a quinolone resistant phenotype due to increased expression and 
activity of EPs.  
Initially, for both mutant strains the MIC values were determined for derivative SZ-7 
and for ciprofloxacin. Taking into account the values obtained, a further determination 
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was performed by adding a single concentration of SZ-7 to the wells containing 
increasing concentrations of ciprofloxacin. This association allowed us to observe a 
significant decrease of the MIC value in the presence of both ciprofloxacin and SZ-7, 
when comparing with the MIC value obtained by ciprofloxacin and SZ-7 separately, 
and also by the results obtained in the control assay that employed TZ. A clear 
synergistic effect between ciprofloxacin and SZ-7 was demonstrated, with reversal of 
resistance of the mutant Salmonella strains. 
When we proceeded in evaluating the inhibitory effect of SZ-7 in both Salmonella 
mutant strains by the fluorometric assay we verified that the hydantoin derivative 
presented indeed the capacity to inhibit the efflux of substrate EtBr, possibly by 
inhibiting the activity of over-expressed EPs. However, it is important to stress the 
differential inhibitory effect of SZ-7 against both mutant strains. According to O‘Regan 
et al (77), the parent Salmonella Enteritidis strains 104 and 5408 displayed high-level 
nalidixic acid resistance, reduced susceptibility to ciprofloxacin and harbored a single 
GyrA mutation (D87Y). After the exposure to ciprofloxacin, both mutant strains were 
genotypically characterized. Mutant 104-CIP harbored two GyrA (D87Y and S83F) 
mutations, and 5408-CIP harbored single GyrA (D87Y), GyrB (E466D), and ParE 
(V461G) mutations. Both mutants over-expressed acrB. The global regulator genes 
soxS and marA were over-expressed in 104-CIP, and ramA was over-expressed in 5408-
CIP. Mutations were found in SoxR (R20H) and in SoxS (E52K) in 104-CIP and in 
RamR (G25A) in 5408-CIP.  
Thus, even though both strains possess an over-expression of the acrB gene, mutational 
differences can influence the inhibitory effect of hydantoin derivative SZ-7. Despite the 
differences observed, in both strains it was possible to note the inhibitory effect of 
derivative SZ-7 in the efflux of EtBr, thus allowing us to conclude that hydantoin 
compound SZ-7 has a direct or indirect effect against the activity of the AcrAB efflux 
system. 
 
The fact that both ciprofloxacin and SZ-7 reduced the MIC value provided an indication 
that this compound possesses a physical-chemical propriety that is worth further study, 
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especially against EPs of cancer cells (98), and revealed that the hydantoin derivative is 
a potential candidate for bacterial EPI with application for the reversal of EP based 
quinolone resistance in Salmonella strains. 
The study of structural analysis and biochemical activity of derivative SZ-7 would 
enable a better understanding and interpretation of the results, apart from the fact that it 
would also provided information regarding the mechanisms inherent to the compound 
that are capable of triggering this inhibitory effect. Since these derivatives were 
specifically synthesized in Poland to be tested as putative EPIs for bacterial and cancer 
cell EPs, their scarcity prevented us from further exploring these hypothesis and the 
remaining SZ-7 was conveyed towards the evaluation of its activity against EPs of 
cancer cells (98). Structural and molecular based activity studies, more specifically 
quantitative structure-activity relationship analysis (QSARS), will be carried out in the 
future after re-synthesizing more compound and patent rights have been assigned by the 
Polish collaborator research group. 
 
After evaluating the newly synthesized hydantoin compounds, we redirected the present 
MSc study towards the research of aspects inherent to the functioning of bacterial cells 
that can influence the screening process of potential EPIs, taking advantage of the fact 
that hydantoins and phenothiazines are heterocyclic compounds (9, 20) with putative 
similar mechanisms of action regarding the neurological system (20, 76). To explore the 
bioenergetic hypothesis of this thesis we have continued the research work using 
phenothiazines and E. coli as the bacterial strain. Hence, we devoted the second part of 
the present study towards the bioenergetic machinery and biochemical requirements 
behind the activation of efflux systems in bacterial cells. 
Having said that, we questioned whether Ca
2+
 ions would have a decisive influence in 
the regulation of the EP systems present in reference strain E. coli AG100, and how this 
regulatory function could affect potential EPIs.  
In bacterial cells, Ca
2+
 is implicated in a wide variety of cellular processes, including the 
cell cycle, cell division (60) and many other mechanisms mentioned earlier. 
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On the other hand, CPZ is recognized for its inhibitory properties on the activity of EP 
systems by restraining the binding of Ca
2+
 to energy providing enzymes (4, 57). In vitro, 
CPZ is capable of promoting the accumulation of bacterial EP substrate EtBr that results 
from the inhibition of bacterial efflux (54). However, previous studies demonstrated that 
the effects of a phenothiazine as efflux inhibitors are not evident at pH 5, regardless of 
whether metabolic energy is present (52). Owing the reason previously stated, in this 
study it was hypothesized that all assays are performed using PBS at a pH 8 and always 
in the presence of glucose as the immediate source of metabolic energy. This requisite 
reflects conditions at the surface of the cell where hydronium ions resulting from 
metabolic activity are stored, and due to the dissociation of these ions into the bulk 
medium at pH 8 they must be restored by glucose via metabolic activity (52). 
These requirements allow the bacterial strain to perform in optimal conditions since 
maintenance of the proton motive force (PMF) is favored, consequently promoting 
efflux activity.  
In the beginning of this study, accumulation of bacterial EP substrate EtBr is confirmed 
in the presence of varying concentrations of CPZ, which resulted in the inhibition of 
efflux. However, when calcium chloride is added to the assay in the presence of CPZ, 
an abrupt decrease in accumulation of EtBr occurs. Because the inhibitory effects of 
CPZ on efflux of EtBr can be abolished by the addition of Ca
2+
, the role of calcium in 
this assay is proven to be being essential for the maintenance of efflux by reference 
strain E. coli AG100. 
The effects of calcium ions were later on confirmed by utilizing Ca
2+
 chelator EDTA as 
the inhibitor of efflux activity. As is the case for CPZ, varying concentrations of EDTA 
present inhibitory effects on efflux of EtBr, although not as evident as with CPZ. For 
this assay it was necessary to use higher concentrations of EDTA, when comparing to 
the MIC values obtained for this compound. Even so, cellular viability is still 
guaranteed owing the fact that for the duration of the assay (approximately 60 minutes) 
the concentrations employed are not capable of affecting the viability of E. coli AG100, 
contrary to the 18 hour incubation period of a MIC determination. Nevertheless, the 
inhibitory effects that EDTA was able to provide in the assays are also completely 
obviated by the addition of Ca
2+
 ions, allowing the cell to evade the inhibition of efflux. 
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Because the inhibitory effects of CPZ on efflux of EtBr can be completely precluded by 
the addition of Ca
2+
 ions, we conclude that the effects of CPZ on EP systems of 
reference strain E. coli AG100 are entirely reversible via the bioenergetic and 
biochemical requirements for active efflux. 
CPZ is only capable of inhibiting efflux activity when the bacterial medium lacks the 
pool of ions it needs to support bacterial growth and replication. Furthermore, we 
consider that when E. coli AG100 is found in standard conditions of growth and 
replication, Ca
2+
 ions that are re-utilized to bind to calcium-dependent enzymes for the 
survival of bacterial strains are inhibited by CPZ, leaving no more available for Ca
2+
-
dependent enzymes responsible for providing energy to the bacterial strain. 
Also, at pH 8 CPZ is capable of demonstrating a strong inhibitory activity on the efflux 
system of reference strain E. coli AG100. This system is primarily maintained due to 
the presence of glucose as the immediate energy source. Hence, by performing the 
assays at this pH, we confirm that the inhibitory activity results from the direct 
inhibition of energy to E. coli, i.e., the inhibition conducted by CPZ acts directly on the 
energy supplying enzymes (bacterial ATPases), an enzymatic process that is dependent 
upon Ca
2+
, and not by a direct influence on the EPs systems themselves. 
The results acquired above provide data that Ca
2+
 plays a key role in the efflux 
mechanism of E. coli reference strain AG100. To complement and confirm this data an 
additional assay was performed by Ana Martins et al (54), which questioned whether 
the initial effects of CPZ on the EP system of E. coli AG100 are in fact reversible upon 
the addition of Ca
2+
 ions. In the efflux assay performed (54), results confirm that the 
addition of Ca
2+
 restores the cells efflux capacity which had been reduced in the 
accumulation phase by the presence of CPZ alone. However, when the assay was 
conducted in the presence of both CPZ and EDTA, the accumulation is much more 
significant and the addition of the same concentration of Ca
2+
 is no longer adequate to 
reverse the inhibitory effects produced. 
Therefore, taking into consideration all the data gathered during this study, it is safe to 
say that Ca
2+
 does in fact possess the capacity to completely obviate and reverse the 
effects of phenothiazine CPZ, a requisite that is not achievable by the addition of 
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glucose as the immediate energy source. Metabolic energy which is provided to E. coli 
AG100 is not solely responsible for energizing the EPs. This system depends on a large 
range of variables, many of which possibly remain unknown. 
In conclusion, this study allowed us to verify that there is a much more complex 
mechanism inherent to all bacterial strains involving the regulation and activation of EP 
systems and its relation with antibiotic resistance. While this mechanism remains 
unknown, the screening and selection of new and potent compounds, like hydantoin 
derivative SZ-7, that might provide the ideal properties and characteristics to become 
excellent EPIs remains a difficult task to accomplish. Overall this work puts in evidence 
that many biochemical and bioenergetic aspects related to the strains physiology need to 





Both gram-positive and gram-negative bacteria resistant to most antibacterial classes 
available have become increasingly prevalent as nosocomial pathogens, particularly 
among immune-compromised and hospitalized patients. Many of these pathogens 
become multi-drug resistant by the increased expression and activity of EPs capable of 
extruding antiseptics, disinfectants and antibiotics. This fact highlights the importance 
and the emergency needed for the development of alternative antimicrobial therapies to 
prevent the growth and expansion of these MDR bacterial strains worldwide. The search 
for new and potent EPIs is much needed as well as the unraveling of the biochemical 
and bioenergetic requirements behind active efflux, in order to effectively design 
efficient combinational/synergistic therapies with antibiotics and EPIs to prevent the 
emergence of these strains. 
Regarding the importance of hydantoin derivatives, these compounds are known to 
possess non-toxic properties and if derivative SZ-7 is shown to be non-toxic (on-going 
work in eukaryotic cells), evaluating its potential to cure mice with an efflux mediated 
MDR Salmonella infection would be worthwhile. Also, the application of quantitative 
structure-activity relationship analysis should be applied in order to correlate the 
biological activity of the compound with a wide variety of physical and chemical 
parameters. 
Regarding the importance of ions (i.e., Ca
2+
) which participate in the complex network 
that is EPs, a better understanding of the metabolic processes involved in the molecular 
basis of efflux transport and inhibition is absolutely necessary to progress in the drug 
development field. This knowledge will make it possible to improve the screening 
process of compounds with potential to behave as inhibitors of EPs.  
The development of non-toxic and specific inhibitors of EPs, particularly those that 
interfere with specific bacterial energy requirements, will facilitate the 
chemotherapeutic antibacterial regimens, not only preventing multi-drug resistance but 
also enhancing the efficacy of normal therapeutic doses against drug resistant bacteria 
and thus allow the reuse of existing chemotherapeutic arsenal contributing to combat 
the scourge of antibiotic resistance in bacteria.  
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